Published in final edited form as:

J Med Chem. 2020 April 23; 63(8): 4315–4333. doi:10.1021/acs.jmedchem.0c00224.

Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC inhibitors using fragment-based methods and structure-based design

Selena Chacón Simon^a, Feng Wang^a, Lance R. Thomas^b, Jason Phan^a, Bin Zhao^a, Edward T. Olejniczak^a, Jonathan D. Macdonald^a, J. Grace Shaw^a, Caden Schlund^a, William Payne^a, Joy Creighton^b, Shaun R. Stauffer^{c,d}, Alex G. Waterson^{c,d}, William P. Tansey^b, Stephen W. Fesik^{a,c,d,*}

^aDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232, United States;

^bDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232, United States;

^cDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232, United States;

^dDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, 37232, United States

*Corresponding Author: stephen.fesik@vanderbilt.edu; Tel: +1 (615) 322-6303.

Present Addresses

J.D.M., S.R.S.: Cleveland Clinic Center for Therapeutics Discovery, Cleveland, OH, 44195, United States F.W.: Novartis Institutes for Biomedical Research, Emeryville, CA, 94608, United States

The Supporting Information is available free of charge on the ACS Publications website at DOI:

- List of Fragment hits; pharmaceutical properties of select compounds; calculated physicochemical properties of selected compounds; histone methyl transferase assay data; X-ray data collection and refinement statistics; chemical structures of N.C and 30; experimental details for the synthesis of negative control.
- Molecular-formula strings

PDB ID codes

PDB code	Compound
4Y7R	MbIIIb MYC peptide
6UJJ	F-1
6UHY	F-2
6UJH	F-5
6UHZ	F-6
6UJL	F-7
6UJK	2i
6UJ4	4
6UIF	8
6UOZ	12

Authors will release the atomic coordinates and experimental data upon article publication.

Abstract

The frequent deregulation of MYC and its elevated expression via multiple mechanisms drives cells to a tumorigenic state. Indeed, MYC is overexpressed in up to ~50% of human cancers and is considered a highly validated anticancer target. Recently, we discovered that WDR5 binds to MYC and is a critical cofactor required for the recruitment of MYC to its target genes and have reported the first small molecule inhibitors of the WDR5-MYC interaction using structure-based design. These compounds display high binding affinity, but have poor physicochemical properties and are hence not suitable for *in vivo* studies. Herein, we conducted an NMR-based fragment screening to identify additional chemical matter and, using a structure-based approach, we merged a fragment hit with the previously reported sulfonamide series. Compounds in this series can disrupt the WDR5-MYC interaction in cells and as a consequence, we observed a reduction of MYC localization to chromatin.

Graphical Abstract

Keywords

WDR5; MYC; structure-based design; NMR-based fragment screening; PPI

INTRODUCTION

The MYC family of transcription factors regulate a vast array of cellular processes, including control of the cell cycle, cell growth, metabolism, differentiation, apoptosis, transformation, and angiogenesis.¹ Dysregulation of MYC proteins causes broad transcriptional reprogramming to drive increased cell proliferation, oftentimes leading to tumor initiation and progression.^{2,3,4} Indeed, MYC is overexpressed in up to ~50% of human cancers, including lymphoma, melanoma, multiple myeloma, neuroblastoma, lung, colon, and breast cancer.^{5–7} Based on these data, MYC is considered to be an attractive target for cancer drug discovery. However, MYC is a challenging drug target since it is intrinsically disordered, without well-defined pockets.⁸ Alternative strategies for MYC inhibition are continuously sought.^{6,9,10} Recently, we reported that WDR5 is a critical cofactor required for the recruitment of MYC to a subset of its genomic targets.¹¹ WDR5 is a scaffolding protein containing seven WD40 repeats arranged in a β -propeller shape, a motif that is commonly found within proteins that mediate protein-protein interactions.¹² WDR5 has more than two dozen primary direct interaction partners whose binding has been mapped to one of two sites: the “WDR5-interacting” site (WIN site) or the “WDR5-binding motif” (WBM site).¹³ Co-immunoprecipitation (Co-IP) studies identified a specific, highly

conserved region of MYC (MYC box IIIb or MbIIIb) that binds at the WBM site of WDR5 (Figure 1).¹¹ Chromatin immunoprecipitation sequencing (ChIP-seq) and mutational experiments showed that MYC requires WDR5 to effectively recognize target genes on chromatin.¹¹ The biological implication of disrupting the WDR5-MYC interaction was tested by CRISPR engineering the endogenous *c-myc* locus in a Burkitt's Lymphoma cell line to carry a switchable *c-myc* allele that is defective for interaction with WDR5.¹⁴ When injected into the flanks of nude mice, the mutant cells displayed delayed tumor growth compared to cells expressing wild type MYC. Switching MYC to the WDR5 defective mutant in preformed tumors caused rapid and complete regression within a week.¹⁴ These mice survived the entire 60 day duration of the experiment, whereas control mice were all sacrificed by day 17 due to heavy tumor burden, effectively demonstrating that MYC can be therapeutically targeted through WDR5 to reverse malignancy.¹⁴ Microarray data from patient-derived pancreatic ductal adenocarcinoma (PDAC) xenografts revealed that WDR5 is overexpressed and required for tumor maintenance. Consequently, silencing WDR5 in pancreatic ductal adenocarcinoma (PDAC) cells showed a reduction of chromatin-bound MYC.¹⁵ In addition, inhibition of the WDR5-MYC interaction by mutation of key residues in MbIIIb caused accumulation of DNA damage, a similar effect to that observed when WDR5 was knocked down. Together, these studies suggest that the disruption of the WDR5-MYC interaction with a small molecule may have utility as a cancer therapy.¹³

We have previously reported the first small molecules that bind to the WBM site of WDR5. These salicylic acid-based compounds, discovered from structure-based optimization of a high-throughput screening hit (**1**), are capable of demonstrating low nanomolar affinity for WDR5 and potent inhibition of histone methyltransferase activity. In addition to inhibiting MYC binding to WDR5 in the biochemical assays, these compounds can inhibit the WDR5-MYC interaction in cellular lysates.¹⁶ However, these bi-aryl sulfonamide series have challenging physicochemical profiles. Multiple subseries of compounds (including acid, amide, and sulfone variants) exhibit very low F_u , and many of the most potent examples contain multiple phenols that may be prone to glucuronidation or other metabolism.^{17,18} To identify additional chemical matter that may aid the discovery of compounds with improved properties, we conducted an NMR-based fragment screening campaign.^{19,20} By merging a fragment hit with the compounds previously reported using structure-guided-design, we have developed a new subseries of compounds that display high nanomolar binding affinity to WDR5. Overall, the compounds in this series showcase improved drug-like properties, and several of them are capable of disrupting the WDR5-MYC interaction in cell lysates. The best-in-class compound disrupts the WDR5-MYC interaction in whole cells and decreases the amount of MYC at genes requiring WDR5 while leaving MYC levels close to normal at genes where recruitment of MYC is independent of WDR5. Thus, the best-in-class compound can be used as a chemical probe to study the implications of disrupting the interaction between WDR5 and MYC in cells.

RESULTS AND DISCUSSION

Hit Identification from NMR-based fragment screening.

The HMQC spectrum of uniformly ^{15}N -labeled WDR5 in complex with unlabeled MYC 'MbIIIb' peptide was obtained, showing peak shifts in specific regions (Figure 2A). Our ~14,000 compound fragment library was screened against WDR5 (aa. 23–334) using SOFAST ^1H – ^{15}N HMQC, collecting the HMQC spectra of ^{15}N -labeled WDR5 protein in the presence of mixtures of 12 fragments. Fragment mixtures that caused similar peak shifts as the unlabeled MYC peptide were identified as WBM site hits. Deconvolution of the mixtures containing such hits was accomplished by individual assessment of the compounds from each hit pool (Figure 2B); thus, identifying 43 hits (0.32% hit rate). Several of the hits that induced large chemical shift perturbations were selected for affinity determination by NMR titration. However, they all showed relatively weak binding, and did not achieve saturable binding at concentrations up to 2 mM, preventing the determination of an accurate K_d . A survey of the chemical structures of the fragment hits reveals some structural diversity; representative fragment hits **F1–8** are shown in Figure 3. The 10-mer MYC peptide contains hydrophobic residues flanking multiple acidic amino acids, with Lys and Arg residues around this hydrophobic cleft. The known native substrate(s) of this site (C-MYC, RBBP5, KANSL2) have previously been shown to have a structurally similar motif (IDVV, VDVT, LDVV respectively).¹¹ Likewise, we observed that the vast majority of the fragment hits contain an acidic functionality coupled to a hydrophobic motif.

Structure Determination of Fragment Complexes.

Five X-ray co-crystal structures of fragments bound to WDR5 (**F1**, **2**, **5**, **6**, and **7**) were determined using co-crystallization and soaking methods (Figure 4). These co-crystal structures confirm the HMQC-indicated binding to the WBM site. However, the fragments are observed to occupy different parts of this cleft. **F1**, **F2**, and **F6** bind to a pocket corresponding to that occupied by the Ile residue (herein designated as S_1) of the conserved 'IDVV' WBM binding sequence (Figure 4A) and engage the amide group of N225 through a hydrogen bond. The cyclohexyl group of **F2** and **F6** fits into this hydrophobic groove very well, and establishes hydrophobic contacts with a Leu residue of WDR5. The trifluoromethyl group of **F1** occupies the same region (Figure 4B, C, and E). In contrast, **F5** and **F7** bind to a different part of the binding cleft. While **F7** retains the hydrogen bond with the amide backbone of N225, both **F5** and **F7** make hydrophobic contacts with the Val-binding shelf of the pocket (designated as S_4), mimicking the IDVV conserved sequence. These two fragments make contacts with the loop region of WDR5, directed towards the central core of the protein that has not been demonstrated to be involved in MYC binding (Figure 4D and F).

Compound Design.

Linking together two fragments bound in close proximity to one another in a protein is a proven strategy that can dramatically improve binding affinity.^{21,22} However, analysis of the X-ray co-crystal structures of the different fragment hits did not directly reveal an obvious opportunity to merge or link multiple fragments. Conversely, the overlay of the co-crystal structures of **F2** with WDR5 and the previously reported biarylsulfonamide, **1**, which was

obtained from our HTS campaign¹⁶ (Figure 5A and 5B) showed that merging this chemical matter may represent a viable path forward (Figure 5C). The phenyl carboxylic acid of **F2** interacts with Asn225 in a manner highly similar to the sulfonamide of **1**, and provides a conformation able to access the S₄ pocket of the WBM binding site. Retention of the bromide-containing aryl group of **1** was desired, as it should allow a halogen bond interaction between the bromine and the carbonyl group from Trp273. This was demonstrated to be a key binding interaction in the previously reported series.¹⁶ For the synthesis of these merged compounds, we decided to incorporate the phenol and the chlorine sulfonyl ring elements found on the best-in-class compounds in previous work.¹⁶ An additional consideration when designing the merged compound was the location of the *N*-substituent of the imidazole ring. The overlapped atoms (Figure 5C) show that the amine could be placed at the position corresponding to either C-4 or C-5 of the imidazole. We designed the compounds with the amine at C-4, due to anticipation of a better angle to fill the S₁ pocket and an easier synthesis.

***N*-substituted imidazolyl analogues.**

A competition fluorescence polarization-based assay (FPA) was used to evaluate the ability of all analogs to disrupt the complex between WDR5 and a FITC-labeled small molecule.¹⁶ From this, the binding affinity of the small molecule can be calculated. The synthesis of the initial merged compound **2a** (Table 1) used sulfonyl chloride **17** (Scheme 1), which represents the best-in-class piece reported in our prior work. Evaluation of **2a** in the FPA showed a binding affinity of 1.00 μ M; representing a several hundred-fold improvement from the fragment **F2** (from which we were unable to ascertain an accurate K_d via this FPA protocol) and a 8-fold improvement from **1** (K_d = 8.5 μ M). We were highly encouraged by this initial success of the fragment-merging design strategy. To optimize the binding affinity of the merged compound, a survey of hydrophobic substituents, including different sizes of carbocycles, as well as various alkyl and acyl groups, were installed at the N-1 of the imidazole ring (Table 1). Inspired by other fragment hits (**SF-9**, see Supplemental Table 1), a phenyl ring was installed (**2b**), which could potentially generate multiple new vectors for optimization of the compounds. However, **2b** showed reduced affinity, perhaps due to a planar relationship with the imidazole ring. An *ortho*-substituted aryl ring (**2c**) was also explored to induce a twist in the angle between the rings and to better occupy the pocket. Unfortunately, this was also detrimental to the binding affinity. Previous success was observed with small, cyclic alkyl groups in S₁.¹⁶ Indeed, flexible, linear chains are not well tolerated in this series (**2d**), and larger groups like dicyclopropylmethane (**2e**) also proved to be deleterious for binding affinity. The better fit of the cyclohexyl group in the S₁ pocket encouraged the study of other acyclic and saturated groups. Smaller substituents, like cyclopropyl (**2g**) and isopropyl (**2f**), appear to not efficiently fill the pocket, as evidenced by the reduced binding affinity to WDR5. Cycloalkanes somewhat smaller than cyclohexane, such as cyclobutane (**2h**) and cyclopentane (**2i**), did show a 2.5-fold improvement in the binding affinity compared to **2a**. We also sought to introduce solvent-facing polarity into the compounds by replacing the lipophilic cyclopentyl ring. However, the pyrrolidine of **2j** was not tolerated. Likewise, the introduction of a methylene spacer between the imidazole and the cycloalkane (**2k-2n**) was detrimental for binding affinity. We also introduced acyl groups near the S₁ pocket to possible engage Q289 with a hydrogen bond; however, **2o** and **2p** were

very weak binders. Interestingly, modification of the phenol to a methoxy led to significant drops in affinity, allowing for the identification of structurally analogous negative control compounds (e.g., **N.C.**, Supplemental Figure 1).

We were able to obtain an X-ray structure of compound **2a** bound to WDR5 (Figure 6). As anticipated, the compound forms a hydrogen bond to the NH of Asn225 and a halogen bond to the carbonyl of Trp273. Notably, the X-ray crystal structure also shows a putative interaction between the imidazole nitrogen and the side chain amine of Lys272. The cyclopentyl group sits in the hydrophobic pocket designated as S₁ (Figure 6), which is partly formed from the hydrophobic side chains of Leu240, Leu249, and Leu288.

Analogs with alternative heterocycles.

Having established preferences for the hydrophobic group at S₁, we transitioned to examining various heterocyclic alternatives to the imidazole ring (Table 2). A 1,2,4-triazole ring (**3a**) demonstrated that a third nitrogen atom was disadvantageous in this pocket, as shown by a ~16-fold decrease in binding affinity relative to **2i**. Based on the X-ray crystal structure of **2i**, one of the nitrogen atoms of **3a** is most likely pointing towards the hydrophobic region, explaining this significant loss of affinity. Incorporation of pyrazole rings allowed us to walk the nitrogen atoms around the ring (**3bd**). The regioisomers **3b** and **3c** did not improve the binding affinity, indicating that the angles and/or the nitrogen distribution were not favorable. On the other hand, analog **3d** showed affinity comparable to **2i**. Likewise, the thiazole **3e** was tolerated, with only a 1.6-fold decrease in binding affinity relative to **2i**. Finally, the larger and more lipophilic benzothiazole **3f** (AlogP = 4.1, compared to AlogP = 3.5 for **2i**, Supplemental Table 3) was not tolerated. Based on this SAR, we decided to retain the imidazole to continue the SAR study.

Growing towards the S₅ pocket.

Examination of the X-ray co-crystal structure of **2i** bound to WDR5 reveals an additional opening in close proximity to the compound, caused by the side-chain rotation of K272 and Q289 (S₅ in Figure 6). We hypothesized that occupation of that region may lead to further increases in affinity, and C-2 of the imidazole ring appears to offer a vector to explore this area. First, small groups like methyl (**4**) and ethyl (**5**) were incorporated onto C-2 of the imidazole (Table 3). Assessment by FPA assay showed that these substitutions are well tolerated. To further guide compound optimization, **4** was co-crystallized with WDR5 and the X-ray structure (Figure 7a) confirmed that the methyl group points towards the S₅ region. Therefore, we proposed that larger and extended linear groups may also be tolerated. An overlay of the crystal structures of **4** and **30** (Supplemental Figure 1)¹⁶ further suggests that incorporation of an amide could allow an additional option to reach to the S₅ region (Figure 7b). Compounds **6**, **7**, and **8** were synthesized to test this idea. Interestingly, the ester and the amide bound better than the acid; this is the opposite observation compared to the bi-aryl sulfonamide series. We were encouraged to design and synthesize three amide analogs (**9**, **10**, and **11**) with the intention to occupy the S₅ region. Unfortunately, the FPA data for these three analogs showed a considerable reduction of the binding affinity. Analog **8** was co-crystallized with WDR5 to help understand the cause of potency loss upon introduction of larger groups (Figure 7c). The crystal structure revealed that the access to S₅ was blocked by

the Q289 side chain, which rotates to engage in a hydrogen bond interaction with the carbonyl oxygen of the methyl amide of **8**, in a similar manner to our previously published compounds. As a consequence of establishing this hydrogen bond, the methyl amide is forced to point towards the solvent rather than along the targeted shelf of the protein. The lack of improvement in binding affinity in **9**, **10**, and **11** can be explained by a blocked access to the S₅ region, and the loss in binding affinity might be related to secondary amines lacking a hydrogen that could form an intramolecular H-bond with the imidazole nitrogen.

Finally, we decided to evaluate methyl sulfone **12** based on the successful incorporation of this group in the previous series. This led to one of the strongest binders observed in this series so far. The X-ray co-crystal structure of **12** with WDR5 shows one of the sulfone's oxygens engaged in a hydrogen bond with Lys272. The position of the sulfone in **12** mimics the position of the amide in the biaryl sulfonamide **30** (Figure 7b, see structure in Supplemental Figure 1) and keeps the S₅ shelf accessible.

The fragment screen allowed the identification of new chemical matter that improved the WDR5-MYC inhibitors. The compounds shown here are weaker binders relative to the best biaryl sulfonamide analogs; however, they have the potential to display improved drug-like characteristics (Supplemental Table 2). While we did not succeed in significantly improving the F_u, we were able to accomplish one of the other goals of the effort: the deletion of one of the phenols. The most potent compounds reported earlier contain two phenols.¹⁶ Likewise, the substitution of the left-hand side phenyl ring for the imidazole furnished compounds with reduced polar surface area relative to the biaryl sulfonamides without raising the lipophilicity (Supplemental Table 3). In addition, most of the compounds shown here were able to maintain good Ligand Efficiencies (LE), which ranged between 0.27 and 0.4, suggesting they remain promising tools for further optimization.

Determination of target engagement.

A collection of eight compounds were assayed in cell lysates of HEK293 (engineered to overexpress HA-tagged c-MYC and Flag-tagged WDR5)¹⁶ to determine whether they could disrupt the interaction between WDR5 and MYC at the protein level. Cell lysates were treated with 50 μ M of compound and WDR5 was immunoprecipitated (Figure 8A). Pleasingly, most of the tested compounds disrupt this interaction (**12**, **6**, **8**, **5**, **2i**, and **3d**), the thiazole **3e** shows no demonstrable effect. The limited disruption shown by the amide was an unexpected result, as its binding affinity is superior ($K_d = 0.17 \mu$ M) to other compounds that did show disruption of the interaction, such as **2i** ($K_d = 0.4 \mu$ M) or **3d** ($K_d = 0.5 \mu$ M). Finally, a structurally related methoxy-containing negative control compound (**N.C.**, $K_d > 40 \mu$ M, Supplemental Figure 1) was tested and, as expected, it did not disrupt the WDR5-MYC complex, confirming the on-target nature of this disruption.

In light of the positive data, we conducted Co-IP experiments in whole cells treated with the same eight compounds, Figure 8B. Compounds **12**, **6**, **8**, **5**, and **2i** decreased complex formation (WDR5-MYC) relative to DMSO. We speculate that the poor performance of **3d** and **3e** is not necessarily due to their physicochemical properties, as the data available for this class of compounds suggest that they are all similar, with high solubility and

permeability and high binding to serum albumin (Supplemental Table 2). However, the lower binding affinity, in combination with other factors such as other non-specific binding to cellular membrane or proteins, efflux, and/or binding kinetics might decrease their activity in cells. We determined that the results shown here were not due to altered protein expression after treatment with compound, as the levels of MYC and WDR5 protein were comparable to DMSO treated cells in the lysates used for immunoprecipitation, confirming an on-target effect.

Since **12** showed the best results at disrupting the MYC-WDR5 interaction in cells, we postulated that it should also break the tether of MYC to chromatin at genomic loci where recruitment of MYC relies on interaction with WDR5. We performed chromatin immunoprecipitation (ChIP) assays and measured MYC binding at known target genes using quantitative PCR. We observed a reduction in the amount of MYC at loci where MYC recruitment is dependent on WDR5 (C7orf40, RNPS1, RPS14, and RPL5)¹⁴ when cells were treated with 20 μ M of **12** for 10 h. Importantly, the amount of MYC remained nearly unaffected at ZFPM1 and ZMF771, two sites where MYC binding is independent of WDR5 (Figure 8C). Finally, this result was not due to altered expression or binding of WDR5 to these loci because ChIP experiments for WDR5 demonstrated comparable levels between cells treated with **12** and N.C. (Figure 8D).

Moreover, similar to the effect observed with the previous molecules we demonstrated a functional effect of **3d**, **6**, **8**, and **12** binding to WDR5, as they inhibited the biochemical histone methyltransferase activity of MLL-1 in the full WDR5, RBBP5, ASH2L, and DPY30 (WRAD) complex (Supplemental Table 4). It is known that a functional WRAD MLL complex requires binding of proteins to both the WIN and WBM site of WDR5^{23–25}; this data confirms that disrupting the interaction at the WBM site can inactivate the transferase activity of the complex, presumably by disrupting the interaction of WDR5-RBBP5, thus preventing the assembly of the WRAD complex.

Chemistry.

The general strategies developed for compound synthesis are illustrated in Schemes 1–3. The synthesis of fragment-merged compounds with different *N*-substituents on the imidazole ring started from the commercially available 4-nitro-1*H*-imidazole, **13** (Scheme 1). Treatment with base and the desired bromoalkene at 135 °C in a microwave reactor gave the compounds **15a**, **15d**, **15f**, and **15h-n**. Bulky haloalkenes exhibited very low yields or did not react using these conditions. Therefore, compounds **15c**, **15e**, and **15g** were synthesized utilizing an ANRORC mechanism (Addition of Nucleophile, Ring Opening, and Ring Closure).²⁶ 4-Nitro-1*H*-imidazole was nitrated to form **14**, and subsequent addition of the desired amine or aniline (**c**, **e**, or **g**) furnished **15c**, **15e**, and **15g**. An Ullman-type coupling was used to synthesize **15b**, and acylation of **13** with cyclobutanecarbonyl chloride or cyclopentanecarbonyl chloride allowed the synthesis of **15o** and **15p**, respectively. The *N*-substituted-4-nitroimidazoles were hydrogenated using heterogeneous catalysis (Pd/C); the addition of aqueous HCl was required to stabilize the compounds **16ap**. The crude hydrogenation products were reacted with sulfonyl chloride **17**, affording the desired sulfonamide analogues **2a-p**. Partial hydrogenation of some 4-nitroimidazole intermediates

or decomposition of the aminium chlorides contributed to low yields observed within this series.

The heterocyclic compounds shown in Table 2, **3a-f**, were synthesized by routes analogous to those used for the imidazoles. The 1,2,4-triazole **18a** was first alkylated with bromocyclopentane and the intermediate was submitted to hydrogenation with addition of 3 M aqueous HCl to produce the aminium chloride **19a**. Reaction with **17** allowed the synthesis of the sulfonamide **3a**. Compounds **3b-e** were synthesized by coupling the commercially available amine or aminium chloride (**19b-e**) with **17**. Analog **3f** required a Suzuki coupling between *tert*-butyl (2-bromothiazol-5-yl)carbamate and cyclopent-1-en-ylboronic acid to produce *tert*-butyl (2-(cyclopent-1-en-1-yl)thiazol-5-yl)carbamate. This intermediate was then deprotected using 4 M HCl in dioxane. The aminium chloride salt was used to avoid poisoning of the catalyst in the hydrogenation step. Finally, **19f** was reacted with the sulfonyl chloride **17** to give the desired product.

The analogs shown in Table 3 were synthesized using multiple approaches. The synthesis of **4** started with 5-methyl-4-nitroimidazole **21**, which was *N*-alkylated with bromocyclopentane and then reduced to the aminium chloride **22**. The desired sulfonamide was obtained by reacting **22** with **17**. Compound **5** was synthesized by *N*-alkylating 2-bromo-4-nitro-1*H*-imidazole (**23**), and subsequent coupling with vinyl boronic pinacol ester using Suzuki conditions (**24**). Hydrogenation of the alkene and nitro groups was achieved in the same step (**25**). Finally, reacting **25** with **17** formed the sulfonamide. Installation of the sulfone group to generate **12** started with *N*-alkylation of **23**, followed by a palladium-catalyzed cross-coupling of 2-bromo-1-cyclopentyl-4-nitro-1*H*-imidazole with sodium methanethiolate. 1-Cyclopentyl-2-(methylthio)-4-nitro-1*H*-imidazole was oxidized using Oxone in EtOH:H₂O to give **26**. The intermediate **27** was accessible by close monitoring of the hydrogenation step; the reaction was stopped after 10–15 min as longer reaction times generated multiple by-products (not-characterized) and disappearance of the desired aminium chloride. The reaction of **17** with **27** allowed the formation of **12**. Finally, the synthesis of compounds **6–11** followed a similar route, in which **28** was *N*-alkylated, reduced (**29**) and reacted with **17** to produce **6**. Hydrolysis using basic conditions allowed the isolation of **7**, and PyBOP (or HATU) mediated coupling of the acid with the desired amine furnished **7–11** after Boc-deprotection when required.

CONCLUSIONS

The high frequency of MYC-related alterations in cancers has made it into one of the most studied gene products in oncology. Different strategies to directly target MYC have been pursued. Despite significant effort, these approaches have proved MYC to be a challenging target, and is considered perhaps “undruggable”. Consequently, the examination of alternative and indirect ways to target MYC has become more prominent recently,^{27–31} and the discovery of WDR5 as a critical co-factor required for the recruitment of MYC to a subset of genomic targets and its later validation through different mutational studies encouraged us to search for small molecules inhibitors of the WDR5-MYC interaction.^{11,14} We sought to identify small molecules inhibitors with drug-like properties that would enable further studies to examine validation of this approach to treat MYC-driven cancers.

We have previously reported the first set of compounds that bind to the WBM-site of WDR5 with low nanomolar affinity.¹⁶ These biaryl sulfonamides proved the feasibility of targeting the challenging and shallow WBM-site and, more importantly, confirmed (by fluorescence polarization assays, differential scanning fluorimetry, histone methyltransferase assays, and CoIP in cell lysates) that disruption of the WDR5-MYC complex with small molecules is possible. While these molecules are some of the most potent reported inhibitors of an external-cleft site of a WD-repeat protein, the undesired physicochemical properties of these compounds (very low free fraction and multiple phenols) discouraged cellular or *in vivo* studies.

In this report, we used structure-based design and new chemical matter identified in an NMR-based fragment screen to discover a new series of compounds through fragment-merging with our previously established series. Compound **12** was best-in-class of the new hybrid-series, exhibiting high binding affinity ($K_d = 0.10 \mu\text{M}$) in the FPA and showed robust disruption of the WDR5-MYC interaction in cell lysates. The improvement in cell activity in this series encouraged studies in a whole cell environment. Co-IP studies in transformed HEK293 cells showed a ~4-fold reduction in the amount of the WDR5-MYC complex when cells were treated with **12**. Further, the compound was shown by ChIP to reduce the amount of MYC bound to chromatin at loci where recruitment of MYC is dependent on WDR5, but did not affect binding of MYC at loci where it binds independently of WDR5. We have confidence that these data replicate our prior results and that compound **12** demonstrates an on-target effect in whole cells.¹⁴ We propose that **12** can be used to further study the cellular implications of disrupting the WDR5-MYC complex and guide further studies towards the development of therapeutic agents to treat MYC-driven cancers.

EXPERIMENTAL SECTION

Protein Expression and Purification

Truncated WDR5 (a.a. 22–334) was cloned into a pET vector with a 6xHis-SUMO tag fused at the N-terminus. The plasmids WDR5 was transformed into *E. coli* BL21 (DE3) cells. The overnight culture was used to start a 10 L fermentation (BioFlo 415, New Brunswick Scientific) grown at 37 °C. For NMR samples, uniformly ¹⁵N-labeled protein was produced in minimal M9 medium, where ¹⁵NH₄Cl (Cambridge Isotope Laboratories) and D-glucose were used as sole nitrogen and carbon sources. When the cell density reached OD₆₀₀ = 2.5, the temperature was lowered to 30 °C. The protein was expressed overnight with 1mM isopropyl-β-D-thiogalactoside (IPTG). M peptide (DEEEIDVVSVE) was ordered (Genscript) as HPLC purified synthetic polypeptide. It was dissolved in DMSO for further use.

Cell pellets were dissolved in lysis buffer (1XPBS plus 300 mM NaCl, 20 mM imidazole, 5 mM BME, and 10% glycerol), and broken by homogenization (APV-2000, APV). The lysate was cleared by centrifugation and filtering, and then applied to an affinity column (140 mL, ProBond, Invitrogen). Bound protein was eluted by an imidazole gradient. The His-SUMO-tag was removed by SUMO protease cleavage during dialysis and the subsequent subtractive second nickel-column. WDR5 protein was then purified by size-exclusion chromatography (HiLoad 26/60, Superdex 75, GE Healthcare) using NMR or crystallization buffer.

NMR Experiments: Fragment Screening and K_d Determination

NMR samples contained 2 mg/mL (~67 μ M) of 15 N-labeled WDR5 in 25 mM phosphate buffer, pH = 6.0, 100 mM NaCl, and 1 mM DTT. The fragment library was screened in the format of 12-compound mixtures, and the mixture hits were then deconvoluted.

Nuclear magnetic resonance (NMR) screening was conducted using a Bruker Avance III 600 MHz NMR spectrometer equipped with a 5mm single-axis z-gradient cryoprobe and a Bruker Sample Jet sample changer. Two dimensional, gradient-enhanced ^1H - ^{15}N heteronuclear multiple-quantum coherence (SOFAST-HMQC)³² spectra were collected at 25 °C and used to track chemical shift perturbation upon fragment binding. Spectra were processed and visualized using Topspin (Bruker BioSpin).

NMR titration of WDR5 fragment hits were performed using SOFAST-HMQC to monitor the chemical shift changes (CSC), and the K_d was calculated using the equation

$$CSC = CSC_{\max}((1)T + (1)T + K_d - \frac{\{((1)T + (1)T + K_d)^2 - 4(1)T(1)T\}}{(2(1)T(2))})$$

Protein Crystallization, Data Collection, and Structure Refinement.—WDR5 was concentrated to 10 mg/mL (~300 μ M) in the buffer of 20 mM HEPES, pH 7.0, 250 mM NaCl, and 5 mM DTT. Apo- and co-crystals were obtained at 18 °C using the hanging drop method. The crystallization condition was 0.1 M Bis-Tris pH 6.0, 0.2 M ammonium acetate, 28% to 32% PEG3350. Soaking was also applied to some compounds using the apo-crystals. Crystals were flash frozen in liquid nitrogen directly.

Diffraction data were collected on the Life Sciences Collaborative Access Team (LS-CAT) 21-ID-D and G beamlines at the Advanced Photon Source (APS), Argonne National Laboratory. Data were indexed, integrated, and scaled with HKL2000.³³ Molecular replacement was achieved with Phaser44 as implemented in CCP4.45³⁴ using a previously determined WDR5 structure (PDB code 3EG6). Refinement of the structural models was conducted with PHENIX³⁵ and included rounds of manual model building in COOT.³⁶ All structure images were prepared with PyMOL.³⁷

Cloning and plasmids

Full length human WDR5 with an N-terminal FLAG tag was cloned into the NgoMIV and SalI sites as a NgoMIV/XhoI fragment. pBabe-GFP was constructed by PCR amplifying the GFP fragment from pEGFPC2 (Clontech) and cloning the product into the EcoRI and BamHI sites of pBabe Puro. Full length human c-MYC with a C-terminal double HA tag was cloned into the BamHI and EcoRI sites of pBabe-IGH.¹¹ HEK293 cells stably expressing MYC2HA were made by retroviral transduction followed by selection in Hygromycin (50 μ g/ mL). The mixed population was then infected with pBabe-Puro expressing GFP or WDR5 with selection in puromycin (1 μ g/ mL). For retroviral transductions, HEK293T cells were transfected with the appropriate pBabe vector, the pCL10A packaging vector, and pMax-GFP to estimate transfection efficiency. Viral supernatant was collected and used to infect HEK293 class over three days.

Cell culture

HEK293 cells expressing HA-tagged MYC with either Flag-tagged WDR5 or GFP by retroviral transduction have been described.¹⁶ Cells were maintained in DMEM supplemented with 10% FBS, Hygromycin B (50 µg/ mL), and puromycin (100 ng/ mL) to maintain transgene expression. Both cell lines were tested and confirmed negative of mycoplasma using the VenorGem PCR test kit (Sigma Aldrich). After thawing from liquid nitrogen, cells were passaged at least twice before use in experiments, and passaged for a maximum of 25 times.

WDR5 Immunoprecipitation

HEK293 cells were harvested and lysates were prepared on ice in lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X100 and supplemented with protease and phosphatase inhibitors). Equal amounts of protein lysate were subject to immunoprecipitation with M2 agarose overnight at 4 °C and immune complexes were recovered, washed in lysis buffer, and resolved by SDS-PAGE. Immunoblotting was performed using the indicated primary antibodies. For experiments in which cells were treated with compound, HEK293 cells were grown to approximately 70% confluence, washed once with PBS then treated for 24 h with compound in OptiMEM media before harvesting.

Antibodies

The following primary antibodies were used for this study: α-C-MYC (#5605), α- WDR5 (#13105), α-HA (#3724) all purchased from Cell Signaling Technology. α-FLAG-HRP (#A8592) and α-FLAG M2 Affinity Gel (#A2220) were from Millipore-Sigma.

Chromatin Immunoprecipitation (ChIP) Experiments

HEK293 cells expressing HA-tagged MYC and GFP were plated in growth media. Upon reaching approximately 70% confluence, cells were washed once with PBS then treated for 10 h with compound in OptiMEM media. Cells were cross linked at room temperature in PBS containing 1% Formaldehyde for 10 minutes, then cells were scraped into 1.5 ml PBS supplemented with 125 mM Glycine. Cells were collected by centrifugation, washed once with PBS + 125 mM Glycine, and pellets stored frozen. Chromatin was prepared by lysing cells at 80×10^6 per ml in ChIP Lysis Buffer (50 mM Tris pH 8.0, 140 mM NaCl, 1mM EDTA, 1% Triton, 1% SDS and supplemented with protease inhibitor cocktail), Samples were sonicated (BioRuptor) for 30 minutes and cleared by centrifugation. Precipitation was performed essentially as described [Thomas LR 2015 Mol Cell] by diluting chromatin 1:9 in ChIP buffer without SDS. Decrosslinked DNA was diluted to 500 µL with water and 7.5 µL was used for each qPCR reaction. Percent input was calculated by comparison to a 30-fold dilution of decrosslinked chromatin. Primers used for ChIP have been described¹⁴.

Fluorescence Polarization Assay

This assay has been previously described.¹¹

Pharmaceutical property determinations

All experiments performed at Q² Solutions Ltd. (<https://www.q2labsolutions.com>) using commercially available, standard assay formats. Kinetic solubility determinations: Method QUI-SOL-001. MDCK permeability determinations: Method QUI-PERM-003. Protein binding assessment: Method QUI-PERM-002.

General Chemistry

All chemical reagents and reaction solvents were purchased from commercial suppliers and used as received. Hydrogenation reactions are performed using an atmospheric balloon. Normal phase flash silica gel-based column chromatography is performed using ready-to-connect cartridges from ISCO, on irregular silica gel, particle size 15–40 μ m using a Teledyne ISCO Combiflash Rf system. Preparative reversed-phase HPLC was performed on a Gilson instrument equipped with a Phenomenex Kinetex C18 column, using gradients of MeCN in H₂O and 0.1% TFA. Compounds that are obtained as a TFA salt after purification were afforded as free base, by dissolving the salt in EtOAc and washing with sat. aq. K₂CO₃. Proton nuclear magnetic resonance (¹H NMR) spectra were recorded at either 400 or 600 MHz on a Bruker spectrometer. For ¹H NMR spectra, chemical shifts are reported in parts per million (ppm) and are reported relative to residual nondeuterated solvent signals. Coupling constants are reported in hertz (Hz). The following abbreviations (or a combination, thereof) are used to describe splitting patterns: s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, multiplet; comp, overlapping multiplets of nonmagnetically equivalent protons; br, broad. All final compounds were of 95% purity or higher, unless otherwise noted, as measured by analytical reversed-phase HPLC. Analytical HPLC was performed on an Agilent 1200 series system with UV detection at 214 and 254 nm, along with evaporative light scattering detection (ELSD). Low-resolution mass spectra were obtained on an Agilent 6140 mass spectrometer with electrospray ionization (ESI). LCMS experiments were performed with the following parameters: Phenomenex Kinetex 2.6 μ m XB-C18 100 Å, LC column 50 mm $\times$ 2.1 mm; a gradient of 5%–95% MeCN in H₂O, and 0.1% TFA, over a 1.2 min or 2.0 min gradient.

General Procedure 1. Chlorosulfonation—Chlorosulfonic acid (7 eq) was cooled to -10 °C in a bath of ice/sat. aq. NaCl. To this was added the corresponding aromatic species (1 eq), portion-wise, as required; the mixture was stirred for 1–16 h. The mixture was quenched by careful addition to a slurry of ice/sat. aq. NaCl/CH₂Cl₂, extracting with CH₂Cl₂. The crude material was purified by ISCO flash chromatography.

General Procedure 2. N-alkylation—In a microwave (MW) vial, the imidazole (1 eq) was added along with the aryl/alkyl halide (1.2 eq), Cs₂CO₃ (3 eq) and KI (4 eq). The solids were suspended in MeCN (0.5 M) and the vial was capped and heated in a microwave reactor for 45 min at 135 °C. Upon cooling, the mixture was filtered and the solvent was removed under vacuum. The crude material was purified by ISCO flash chromatography.

General Procedure 3. Hydrogenation for synthesis of compounds—The corresponding intermediate (1 eq) was added to a vial, followed by Pd/C (10% C by wt., 0.05 eq). The solids were suspended in EtOH (at 0.3 M) and the mixture was stirred under a

H₂ atmosphere for 10 min-2 h. Once the product was observed by LCMS, 10 eq of HCl at 3 M were added. The mixture was filtered through celite, concentrated, and purified by ISCO flash chromatography if required.

General Procedure 4. Sulfonamide Coupling—The corresponding aniline (1 eq) and sulfonyl chloride (1.2–1.5 eq) were combined in CH₂Cl₂ (at 0.2 M) at r.t., pyridine (3 eq) was added, and the mixture was stirred for 1–16 h. The mixture was concentrated *in vacuo* and purified by ISCO flash chromatography, unless stated.

General Procedure 5. Nitration—Similar to the procedure previously reported²⁶, a solution of 4-nitroimidazole (1 eq) and HOAc (35 eq) was cooled to 0 °C. HNO₃ (14 eq) and Ac₂O (14.3 eq) were added and stirring was continued at 0 °C for 10 min. The reaction mixture was then allowed to reach room temperature and stirred for 1 hour. The reaction was quenched by the addition of water and extracted with EtOAc. The organic phase was dried with Na₂SO₄ and filtered, and the solvent removed under vacuum. The crude material was used without further purification.

General Procedure 6. N-alkylation of 1,4-Dinitro-1H-imidazole—Similar to the procedure previously reported,²⁶ 1,4-dinitro-1H-imidazole (1 eq) was dissolved in MeOH:H₂O (1:1 at 0.3 M) and cooled to 0 °C. The amine/aniline (1.1 eq) was added dropwise and the mixture was stirred overnight. Water was added and the mixture was extracted with EtOAc. The organic phase was dried with Na₂SO₄ and filtered, and the solvent removed under vacuum. The crude material was purified using ISCO flash chromatography.

General Procedure 7. Ester Hydrolysis—The ester intermediate (1 eq) was stirred with LiOH (2 M, 5 eq) in THF (at 0.2 M) for 1–16 h at room temperature. The mixture was acidified with hydrochloric acid, extracted with EtOAc, and washed with brine. The crude material was purified by preparative HPLC.

General Procedure 8. PyBOP Mediated Amide Coupling—The corresponding carboxylic acid (1 eq), PyBOP (1.5 eq) and DIPEA (2 eq) were combined in CH₂Cl₂ (at 0.2 M), followed by the addition of amine (1.5 eq). The solution was stirred at r.t. for 16 h, then diluted with CH₂Cl₂, washed with sat. aq. NaHCO₃, and concentrated. Crude product was purified by ISCO flash chromatography or preparative HPLC.

General Procedure 9. Methyl sulfide Coupling—The aryl/heteroaryl iodide or bromide (1 eq) was combined with sodium methanethiolate (1.05 eq), Pd₂(dba)₃ (0.025 eq), and Xantphos (0.05 eq). The vial/container was purged with Ar. Then, THF (to 0.34 M) and Et₃N (1.25 eq) were added and the mixture was heated to 76 °C for 18 h. Upon cooling the mixture was filtered and the solvent was removed under vacuum. The crude was purified using ISCO Flash chromatography.

General Procedure 10. Sulfide to Sulfone—The sulfide was dissolved in H₂O:EtOH (1:1 at 0.32 M) and Oxone (2 eq) was added. The mixture was stirred at r.t. for 4–20 h. Water was added and the mixture was extracted with CH₂Cl₂. The organic phase was dried

using a phase separator and the solvent was removed under vacuum. If required, crude material was purified by ISCO flash chromatography.

General Procedure 12. Suzuki coupling—In a vial, Na₂CO₃ (3 eq) was dissolved in water (2.0 M). Then, dioxane (0.24 M) was added, followed by the addition of the bromothiazole (1 eq), Pd(PPh₃)₄ (0.05 eq) and the boronic acid (1.2 eq). The reaction mixture was degassed with Argon and then heated at 100 °C for 18 h. The mixture was diluted with EtOAc and then washed with a saturated solution of NH₄Cl. The organic phase was dried over a phase separator and the solvent removed under vacuum. The crude material was purified using ISCO flash chromatography.

General Procedure 13. Boc-deprotection—In a vial, the Boc-protected amine (1 eq) was dissolved in a solution of HCl 4 M in dioxane. The reaction mixture was heated to 50 °C for 1–4 hours. The solvent was removed under vacuum to obtain crude material that was purified by ISCO flash chromatography.

Table 1 Examples

5-Bromo-3-chloro-2-hydroxybenzenesulfonyl chloride (6)—Prepared from 2-chloro-4-bromophenol (2.08 g, 10 mmol) according to *General Procedure 1*. After purification, 2.19 g (7.15 mmol, 72% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 (1H, d, *J* = 2.4 Hz), 7.86 (1H, d, *J* = 2.4 Hz); LCMS *t*_R = 1.50 min, *m/z* = *n/a*; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclohexyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (7a)

Step A: 1-Cyclohexyl-4-nitro-1*H*-imidazole (15a): 4-Nitroimidazole (100 mg, 0.88 mmol) was dissolved in 2.2 mL of DMF and K₂CO₃ (183 mg, 1.33 mmol, 1.5 eq) and TBAB (3 mg, 0.01 mmol, 0.01 eq) were added. The mixture was pre-stirred for ~30 min and bromocyclohexane (180 mg, 1.11 mmol, 1.25 eq) was added. The mixture was stirred at 80 °C for 3 days. Upon cooling of the mixture, water was added and DCM was used to extract the product. Then, the organic phase was dried over a phase separator and the solvent was removed under reduced pressure. The crude was taken forward (175 mg). LCMS (Method B): *t*_R = 1.214 min, *m/z* = 196.2 [M+H]⁺.

Step B: 1-Cyclohexyl-1*H*-imidazol-4-aminium chloride (5a): 1-Cyclohexyl-4-nitro-1*H*-imidazole (175 mg, crude) was reacted following *General Procedure 3*. The crude material (24 mg) was taken forward. LCMS *t*_R = 0.565 min, *m/z* = 166.2 [M+H]⁺.

Step C: 5-Bromo-3-chloro-*N*-(1-cyclohexyl-1*H*-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-Cyclohexyl-1*H*-imidazol-4-aminium chloride (24 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 4 mg (0.0092 mmol, 1% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.61 (d, *J* = 2.4 Hz, 1H), 7.57 (d, *J* = 2.4 Hz, 1H), 7.52 (d, *J* = 1.5 Hz, 1H), 6.76 (d, *J* = 1.6 Hz, 1H), 3.93–3.81 (m, 1H), 2.12 (d, *J* = 12.3 Hz, 2H), 1.93 (d, *J* = 13.5 Hz, 2H), 1.76 (d, *J* = 13.2 Hz, 1H), 1.68 –

1.53 (m, 2H), 1.49 – 1.35 (m, 2H), 1.32 – 1.21 (m, 1H). LCMS t_R = 0.951 min, m/z = 434.2, 435.3 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-phenyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2b)

Step A: 1-Phenyl-4-nitro-1*H*-imidazole (15b): 4-Nitroimidazole (200 mg, 1.77 mmol) was mixed with iodobenzene (1.77 mmol, 1 eq), CuI (0.27 mmol, 0.15 eq), *L*-proline (0.27 mmol, 0.15 eq) and K_2CO_3 (3.54 mmol, 2 eq). The vial was purged with argon and then DMSO (1.4 M) was added. It was capped and stirred overnight at 85 °C. The next day, the reaction mixture was diluted with EtOAc and then filtered. The filtrate was washed with brine and the organic phase was dried over Na_2SO_4 . The solvent was then removed under vacuum and the residue was purified using ISCO flash chromatography 62 mg (0.33 mmol, 19% yield) of the title compound was obtained as a colorless solid. 1H NMR (400 MHz, Chloroform-*d*) δ 8.11 (s, 1H), 7.84 – 7.75 (m, 1H), 7.62 – 7.54 (m, 2H), 7.54 – 7.49 (m, 1H), 7.45 (dd, J = 7.2, 1.9 Hz, 2H). LCMS t_R = 0.127 min, m/z = 190.2 $[M+H]^+$.

Step B: 1-Phenyl-1*H*-imidazol-4-aminium chloride (5b): 1-Phenyl-4-nitro-1*H*-imidazole (62 mg, 0.33 mmol) was reacted following *General Procedure 3*. The crude material (64 mg) was taken forward. LCMS t_R = 0.097 min, m/z = 160.2 $[M+H]^+$.

Step C: 5-Bromo-3-chloro-*N*-(1-phenyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide: Phenyl-1*H*-imidazol-4-aminium chloride (64 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 50 mg (0.12 mmol, 35% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform-*d*) δ 9.83 (s, 2H), 8.06 (d, J = 1.7 Hz, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.59 – 7.48 (m, 3H), 7.46 – 7.38 (m, 2H), 7.31 (d, J = 1.7 Hz, 1H). LCMS t_R = 1.570 min, m/z = 427.8, 428.8 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-2-hydroxy-*N*-(1-(2-(trifluoromethyl)phenyl)-1*H*-imidazol-4-yl)benzenesulfonamide (2c).

Step A: 4-Nitro-1-(2-(trifluoromethyl)phenyl)-1*H*-imidazole (15c): 1,4-Dinitro-1*H*-imidazole (100 mg, 0.63 mmol) was reacted with 2-(trifluoromethyl)aniline (1.10 mmol) according to *General Procedure 6*. After purification, 20 mg (0.08 mmol, 12% yield) of the title compound was obtained as a yellow solid. 1H NMR (400 MHz, Chloroform-*d*) δ 7.96 – 7.87 (m, 2H), 7.87 – 7.70 (m, 2H), 7.58 (dd, J = 1.6, 0.8 Hz, 1H), 7.52 – 7.45 (m, 1H). LCMS t_R = 0.777 min, m/z = 258.2 $[M+H]^+$. **Step B:** 1-(2-(Trifluoromethyl)phenyl)-1*H*-imidazole-4-aminium chloride (5c) 4-Nitro-1-(2-(trifluoromethyl)phenyl)-1*H*-imidazole (20 mg, 0.08 mmol) was reacted following *General Procedure 3*. The crude material (22 mg) was taken forward. LCMS t_R = 0.254 min, m/z = 228.3 $[M+H]^+$.

Step C: 5-Bromo-3-chloro-2-hydroxy-*N*-(1-(2-(trifluoromethyl)phenyl)-1*H*-imidazol-4-yl)benzenesulfonamide: 1-(2-(Trifluoromethyl)phenyl)-1*H*-imidazole-4-aminium chloride (22 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 18 mg (0.036 mmol, 45% yield) of the

title compound was obtained. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.86 (d, J = 7.7 Hz, 1H), 7.74 (t, J = 7.7 Hz, 1H), 7.71 – 7.63 (m, 3H), 7.50 (s, 1H), 7.45 (d, J = 7.7 Hz, 1H), 7.13 (s, 1H). ^{19}F NMR (376 MHz, Chloroform-*d*) δ -59.42 (3F). LCMS t_R = 1.138 min, m/z = 496.2, 497.2 $[\text{M}+\text{H}]^+$, Purity (AUC) 95%.

5-Bromo-3-chloro-2-hydroxy-*N*-(1-isopentyl-1*H*-imidazol-4-yl)benzenesulfonamide (2d)

Step A: 1-Isopentyl-4-nitro-1*H*-imidazole (15d): 4-Nitro-1*H*-imidazole (200 mg, 1.57 mmol) was reacted with 1-bromo-3-methylbutane (2.05 mmol) following *General Procedure 2*. After purification, 182 mg (0.99 mmol, 63% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.76 (d, J = 1.6 Hz, 1H), 7.41 (d, J = 1.6 Hz, 1H), 4.04 – 3.97 (m, 2H), 1.73 – 1.64 (m, 2H), 1.54 (dt, J = 13.3, 6.7 Hz, 1H), 0.90 (dd, J = 6.7, 0.9 Hz, 6H). LCMS t_R = 1.303 min, m/z = 184.2 $[\text{M}+\text{H}]^+$.

Step B: 1-Isopentyl-1*H*-imidazol-4-aminium chloride (5d): 1-Isopentyl-4-nitro-1*H*-imidazol (100 mg, 0.54 mmol) was reacted following *General Procedure 3*. The crude material (103 mg) was taken forward. LCMS t_R = 0.192 min, m/z = 154.3 $[\text{M}+\text{H}]^+$.

Step C: 5-Bromo-3-chloro-2-hydroxy-*N*-(1-isopentyl-1*H*-imidazol-4-yl)benzenesulfonamide: 1-Isopentyl-1*H*-imidazol-4-aminium chloride (103 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl following *General Procedure 4*. After purification, 6 mg (0.014 mmol, 3% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform-*d*) δ 8.07 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.01 (s, 1H), 4.07 (t, J = 7.6 Hz, 2H), 1.75 (dt, J = 8.7, 6.7 Hz, 2H), 1.63 – 1.52 (m, 1H), 0.97 (d, J = 6.7 Hz, 6H). LCMS t_R = 0.923 min, m/z = 422.2, 423.3 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-(dicyclopropylmethyl)-1-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2e)

Step A: 1-(Dicyclopropylmethyl)-4-nitro-1*H*-imidazole (15e): 1,4-Dinitro-1*H*-imidazole (100 mg, 0.63 mmol) was reacted with dicyclopropylmethanamine (1.10 mmol) according to *General Procedure 6*. After purification, 37 mg (0.18 mmol, 28% yield) of the title compound was obtained as a yellow solid. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.97 (d, J = 1.6 Hz, 1H), 7.60 (d, J = 1.6 Hz, 1H), 2.85 (t, J = 8.9 Hz, 1H), 1.30 – 1.17 (m, 2H), 0.87 – 0.75 (m, 2H), 0.73 – 0.62 (m, 2H), 0.56 – 0.45 (m, 2H), 0.43 – 0.32 (m, 2H).

Step B: 1-(Dicyclopropylmethyl)-1*H*-imidazol-4-aminium chloride (5e): 1-(Dicyclopropylmethyl)-4-nitro-1*H*-imidazole (37 mg, 0.18 mmol) was reacted following *General Procedure 3*. The crude material (44 mg) was taken forward. LCMS t_R = 0.232 min, m/z = 178.3 $[\text{M}+\text{H}]^+$.

Step C: 5-Bromo-3-chloro-*N*-(1-(dicyclopropylmethyl)-1-imidazol-4-yl)-2-hydroxybenzenesulfonamide: 1-(Dicyclopropylmethyl)-1*H*-imidazol-4-aminium chloride (44 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure D*. After purification, 8 mg (0.018 mmol, 10% yield) of the

title compound was obtained. ^1H NMR (400 MHz, Methanol- d_4) δ 8.66 (d, J = 1.7 Hz, 1H), 7.82 (d, J = 2.5 Hz, 1H), 7.73 (d, J = 2.5 Hz, 1H), 7.30 (d, J = 1.7 Hz, 1H), 3.01 (t, J = 9.3 Hz, 1H), 1.39 – 1.26 (m, 2H), 0.82 – 0.72 (m, 2H), 0.62 – 0.48 (m, 4H), 0.37 – 0.25 (m, 2H). LCMS t_R = 1.615 min, m/z = 445.8, 446.8 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-2-hydroxy-*N*-(1-isopropyl-1*H*-imidazol-4-yl)benzenesulfonamide (2f)

Step A: 1-Isopropyl-4-nitro-1*H*-imidazole (15f): 4-Nitroimidazole (200 mg, 1.77 mmol) was reacted with 2-bromopropane (2.12 mmol) following *General Procedure 2*. After purification, 225 mg (1.45 mmol, 82% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform- d) δ 7.82 (d, J = 1.6 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 4.43 (p, J = 6.7 Hz, 1H), 1.55 (d, J = 6.7 Hz, 6H). LCMS t_R = 0.366 min, m/z = 156.3 $[\text{M}+\text{H}]^+$.

Step B: 1-Isopropyl-1*H*-imidazol-4-aminium chloride (5f): 1-Isopropyl-4-nitro-1*H*-imidazole (225 mg, 1.45 mmol) was reacted following *General Procedure 3*. The crude material (295 mg) was taken forward. LCMS t_R = 0.086 min, m/z = 126.3 $[\text{M}+\text{H}]^+$.

Step C: 5-Bromo-3-chloro-2-hydroxy-*N*-(1-isopropyl-1-imidazol-4-yl)benzenesulfonamide: 1-Isopropyl-1*H*-imidazol-4-aminium chloride (50 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 21 mg (0.053 mmol, 4% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform- d) δ 9.77 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.64 (d, J = 2.4 Hz, 1H), 7.05 (d, J = 1.8 Hz, 1H), 4.46 (p, J = 6.7 Hz, 1H), 1.57 (d, J = 6.7 Hz, 6H). LCMS t_R = 0.809 min, m/z = 394.1, 396.2 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclopropyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2g)

Step A: 1,4-Dinitro-1*H*-imidazole (3): 4-Nitroimidazole (500 mg, 4.42 mmol) was reacted following *General Procedure 5*. Further purification was not required. 538 mg (3.40 mmol, 77% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform- d) δ 8.51 (d, J = 1.7 Hz, 1H), 8.38 (d, J = 1.7 Hz, 1H). LCMS t_R = 0.081 min, m/z = 158.3 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

Step B: 1-Cyclopropyl-4-nitro-1*H*-imidazole (15g): 1,4-Dinitro-1*H*-imidazole (150 mg, 0.39 mmol) was reacted with cyclopropanamine (1.04 mmol) according to *General Procedure 6*. After purification, 105 mg (0.69 mmol, 72% yield) of the title compound was obtained as a yellow solid. ^1H NMR (400 MHz, Chloroform- d) δ 7.78 (d, J = 1.2 Hz, 1H), 7.48 (s, 1H), 3.50 – 3.40 (m, 1H), 1.15 – 1.07 (m, 2H), 1.03 (dt, J = 6.0, 4.1 Hz, 2H). LCMS t_R = 0.109 min, m/z = 154.2 $[\text{M}+\text{H}]^+$.

Step C: 1-(Cyclopropyl)-1*H*-imidazol-4-aminium chloride (5g): 1-Cyclopropyl-4-nitro-1*H*-imidazole (50 mg, 0.33 mmol) was reacted following *General Procedure 3*. The crude material (29 mg) was taken forward. LCMS t_R = 0.086 min, m/z = 124.2 $[\text{M}+\text{H}]^+$.

Step D: 5-Bromo-3-chloro-*N*-(1-(cyclopentanecarbonyl-1*H*-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-Cyclopropyl-1*H*-imidazol-4-aminium chloride (29 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 13 mg (0.033 mmol, 10% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.93 (s, 1H), 7.73 (d, *J* = 2.4 Hz, 1H), 7.65 (d, *J* = 2.4 Hz, 1H), 7.07 (d, *J* = 1.5 Hz, 1H), 3.57 – 3.47 (m, 1H), 1.26 – 1.14 (m, 2H), 1.14 – 1.06 (m, 2H). LCMS *t*_R = 0.808 min, *m/z* = 392.2, 393.4 [M+H]⁺; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclobutyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2h)

Step A: 1-Cyclobutyl-4-nitro-1*H*-imidazole (15h): 4-Nitroimidazole (100 mg, 0.88 mmol) was reacted with bromocyclobutane (1.11 mmol) following *General Procedure 2*. After purification, 100 mg (0.59 mmol, 67% yield) of the title compound was obtained. LCMS *t*_R = 0.097 min, *m/z* = 168.2 [M+H]⁺.

Step B: 1-Cyclobutyl-1*H*-imidazol-4-aminium chloride (5h): 1-Cyclobutyl-4-nitro-1*H*-imidazole (100 mg, 0.59 mmol) was reacted following *General Procedure 3*. The crude material (50 mg) was taken forward. LCMS *t*_R = 0.090 min, *m/z* = 138.1 [M+H]⁺.

Step C: 5-Bromo-3-chloro-*N*-(1-cyclobutyl-1*H*-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-Cyclobutyl-1*H*-imidazol-4-aminium chloride (50 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 14.0 mg (0.033 mmol, 6% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.62 (s, 1H), 7.54 (s, 1H), 7.39 (s, 1H), 6.81 (s, 1H), 4.56 – 4.47 (m, 1H), 2.50 (s, 2H), 2.37 – 2.28 (m, 2H), 1.89 (dt, *J* = 18.7, 9.5 Hz, 2H). LCMS *t*_R = 1.385 min, *m/z* = 405.7, 406.8 [M+H]⁺; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclopentyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2i)

Step A: 1-Cyclopentyl-4-nitro-1*H*-imidazole (15i): 4-Nitroimidazole (900 mg, 7.96 mmol) was reacted with bromocyclopentane (10.35 mmol) following *General Procedure 2*. After purification, 1277 mg (7.05 mmol, 71% yield) of the title compound was obtained as a pale-yellow liquid. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.77 (s, 1H), 7.45 (s, 1H), 4.54 – 4.47 (m, 1H), 2.24 (q, *J* = 8.0 Hz, 2H), 1.89 – 1.68 (m, 6H). LCMS *t*_R = 0.591 min, *m/z* = 182.3 [M+H]⁺.

Step B: 1-Cyclopentyl-1*H*-imidazol-4-aminium chloride (5i): 1-Cyclopentyl-4-nitro-1*H*-imidazole (50 mg, 0.28 mmol) was reacted according to *General Procedure 3*. The crude material (51 mg) was taken forward. LCMS *t*_R = 0.114 min, *m/z* = 152.3 [M+H]⁺.

Step C: 5-Bromo-3-chloro-*N*-(1-cyclopentyl-1*H*-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-Cyclopentyl-1*H*-imidazol-4-aminium chloride (51 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following

General Procedure 4. After purification, 13.8 mg (0.033 mmol, 12% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.61 (d, J = 2.4 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.51 (d, J = 1.6 Hz, 1H), 6.75 (d, J = 1.6 Hz, 1H), 4.41 (p, J = 6.7 Hz, 1H), 2.25 – 2.15 (m, 2H), 1.91 – 1.71 (m, 6H). LCMS: t_R = 0.874 min, m/z = 420.1, 422.1 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-2-hydroxy-*N*-(1-(pyrrolidin-3-yl)-1*H*-imidazol-4-yl)benzenesulfonamide (2j).

Step A: *tert*-Butyl 3-(4-nitro-1*H*-imidazole-1-yl)pyrrolidine-1-carboxylate: 4-Nitroimidazole (150 mg, 1.33 mmol) was reacted with *tert*-butyl 3-bromopyrrolidine-1-carboxylate (1.59 mmol) following *General Procedure 2*. After purification, 185 mg (1.17 mmol, 88% yield) of the title compound was obtained. LCMS t_R = 0.800 min, m/z = 283.3 $[\text{M}+\text{H}]^+$.

Step B: 1-(Pyrrolidin-3-yl)-1*H*-imidazol-4-aminium chloride (15j): *tert*-Butyl 3-(4-nitro-1*H*-imidazole-1-yl)pyrrolidine-1-carboxylate (185 mg, 1.17 mmol) was reacted following *General Procedure 3*. The Boc-protected crude material (183 mg) was taken forward. LCMS t_R = 0.084 min, m/z = 153.3 $[\text{M}+\text{H}]^+$.

Step C: 5-Bromo-3-chloro-2-hydroxy-*N*-(1-(pyrrolidin-3-yl)-1*H*-imidazol-4-yl)benzenesulfonamide: 1-(Pyrrolidin-3-yl)-1*H*-imidazol-4-aminium chloride (183 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 8 mg (0.019 mmol, 2% yield) of the title compound was obtained. ^{13}C NMR (151 MHz, Chloroform-*d*) δ 150.23, 148.22, 138.12, 134.96, 129.75, 125.10, 122.99, 117.44, 111.90, 56.85, 53.37, 45.83, 32.24. ^1H NMR (600 MHz, Chloroform-*d*) δ 7.81 (d, J = 1.6 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 2.4 Hz, 1H), 7.58 (d, J = 1.6 Hz, 1H), 4.93 – 4.87 (m, 1H), 3.80 (dd, J = 11.1, 6.3 Hz, 1H), 3.74 – 3.66 (m, 2H), 3.53 – 3.45 (m, 1H), 2.65 – 2.56 (m, 1H), 2.37 – 2.29 (m, 1H), 1.44 (s, 1H). LCMS t_R = 0.918 min, m/z = 453.2, 455.2 $[\text{M}+\text{CH}_3\text{OH}+\text{H}]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-(cyclopropylmethyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2k).

Step A: 1-(Cyclopropylmethyl)-4-nitro-1*H*-imidazole (15k): 4-Nitroimidazole (200 mg, 1.77 mmol) was reacted with 1-bromo-1-cyclopropylmethane (2.30 mmol) following *General Procedure 2*. After purification, 226 mg (1.35 mmol, 76% yield) of the title compound was obtained. LCMS t_R = 0.485 min, m/z = 168.4 $[\text{M}+\text{H}]^+$.

Step B: 1-(Cyclopropylmethyl)-1*H*-imidazol-4-aminium chloride (5k): 1-Cyclopropylmethyl-4-nitro-1*H*-imidazole (66 mg, 0.39 mmol) was reacted following *General Procedure*

3. The crude material (60 mg) was taken forward. LCMS t_R = 0.089 min, m/z = 138.2 $[\text{M}+\text{H}]^+$.

Step C: 5-Bromo-3-chloro-*N*-(1-(cyclopropylmethyl)-1*H*-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-(Cyclopropylmethyl)-1*H*-imidazol-4-aminium chloride (60 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 8 mg (0.020 mmol, 5% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.18 (s, 1H), 7.73 (d, *J* = 2.4 Hz, 1H), 7.65 (d, *J* = 2.4 Hz, 1H), 7.11 (d, *J* = 1.7 Hz, 1H), 3.92 (d, *J* = 7.4 Hz, 2H), 1.30 – 1.19 (m, 1H), 0.87 – 0.81 (m, 2H), 0.46 (q, *J* = 5.4 Hz, 2H). LCMS *t*_R = 0.758 min, *m/z* = 406.2 [M+H]⁺; 95% (AUC).

5-Bromo-3-chloro-*N*-(1-(cyclobutylmethyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2l).

Step A: 1-(Cyclobutylmethyl)-4-nitro-1*H*-imidazole (15l): 4-Nitro-1*H*-imidazole (200 mg, 1.77 mmol) was reacted with (bromomethyl)cyclobutane (2.30 mmol) following *General Procedure 2*. After purification, 320 mg (1.77 mmol, quant.) of the title compound was obtained. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.13 (s, 1H), 7.74 (s, 1H), 4.13 (d, *J* = 7.6 Hz, 2H), 2.79 (p, *J* = 7.7 Hz, 1H), 2.11 – 2.00 (m, 2H), 1.97 – 1.75 (m, 4H). LCMS (Method B) *t*_R = 0.223 min, *m/z* = 182.3 [M+H]⁺.

Step B: 1-(Cyclobutylmethyl)-1*H*-imidazol-4-aminium chloride (5l): 1-

(Cyclobutylmethyl)-4-nitro-1*H*-imidazol (320 mg, 1.77 mmol) was reacted following *General Procedure*

3. The crude material (500 mg) was taken forward. LCMS *t*_R = 0.090 min, *m/z* = 152.3 [M+H]⁺.

Step C: 5-Bromo-3-chloro-*N*-(1-(cyclobutylmethyl)-1*H*-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-(Cyclobutylmethyl)-1*H*-imidazol-4-aminium chloride (100 mg, crude) with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 26 mg (0.062 mmol, approximately 18% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.88 (d, *J* = 2.4 Hz, 1H), 7.77 (d, *J* = 2.4 Hz, 1H), 7.32 (d, *J* = 1.7 Hz, 1H), 6.76 (s, 1H), 6.72 (d, *J* = 1.7 Hz, 1H), 3.92 (d, *J* = 7.6 Hz, 2H), 2.70 (p, *J* = 7.6 Hz, 1H), 2.18 – 2.05 (m, 2H), 2.04 – 1.86 (m, 2H), 1.81 – 1.70 (m, 2H). LCMS *t*_R = 1.111 min, *m/z* = 421.2, 422.3 [M+H]⁺; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-(cyclopentylmethyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2m).

Step A: 1-(Cyclopentylmethyl)-4-nitro-1*H*-imidazole (15m): 4-Nitro-1*H*-imidazole (200 mg, 1.77 mmol) was reacted with (bromomethyl)cyclopentane (2.30 mmol) following *General Procedure 2*. After purification, 305 mg (1.56 mmol, 88% yield) of the title compound was obtained. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.18 (d, *J* = 1.5 Hz, 1H), 7.76 (d, *J* = 1.5 Hz, 1H), 4.05 (d, *J* = 7.7 Hz, 2H), 2.37 (p, *J* = 7.7 Hz, 1H), 1.80 – 1.54 (m, 6H), 1.33 – 1.20 (m, 2H). LCMS *t*_R = 0.722 min, *m/z* = 196.3 [M+H]⁺.

Step B: 1-(Cyclopentylmethyl)-1*H*-imidazol-4-aminium chloride (5m): 1-

(Cyclopentylmethyl)-4-nitro-1*H*-imidazole 305 mg (1.56 mmol) was reacted following

General Procedure 3. The crude material (204 mg) was taken forward. LCMS t_R = 0.095 min, m/z = 166.3 $[M+H]^+$.

Step C: 5-Bromo-3-chloro-N-(1-(cyclopentylmethyl)-1H-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-(Cyclopentylmethyl)-1H-imidazol-4-aminium chloride (102 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 18 mg (0.041 mmol, 15% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform- d) δ 7.92 (d, J = 2.4 Hz, 1H), 7.77 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 1.7 Hz, 1H), 6.74 (d, J = 1.7 Hz, 1H), 3.83 (d, J = 7.7 Hz, 2H), 2.26 (p, J = 7.7 Hz, 1H), 1.83 – 1.71 (m, 2H), 1.71 – 1.55 (m, 4H), 1.26 – 1.13 (m, 2H). LCMS t_R = 1.151 min, m/z = 435.2, 436.2 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-2-hydroxy-N-(1-((tetrahydrofuran-2-yl)methyl)-1H-imidazol-4-yl)benzenesulfonamide (2n)

Step A: 4-Nitro-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole (15n): 4-Nitro-1H-imidazole (200 mg, 1.77 mmol) was reacted with 2-(bromomethyl)tetrahydrofuran (2.30 mmol) following *General Procedure 2*. After purification, 280 mg (1.093 mmol, 0.62% yield) of the title compound mixed with its regioisomer (3:1, determined by 1H -NMR) was obtained. LCMS t_R = 0.098 min, m/z = 198.3 $[M+H]^+$.

Step B: 1-((Tetrahydrofuran-2-yl)methyl)-1H-imidazol-4-aminium chloride (5n): 4-Nitro-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole (280 mg, 1.09 mmol, regioisomer mixture) was reacted following *General Procedure 3*. The crude material (205 mg) was taken forward. LCMS t_R = 0.088 min, m/z = 168.2 $[M+H]^+$.

Step C: 5-Bromo-3-chloro-2-hydroxy-N-(1-((tetrahydrofuran-2-yl)methyl)-1H-imidazol-4-yl)benzenesulfonamide: 1-((Tetrahydrofuran-2-yl)methyl)-1H-imidazol-4-aminium chloride (100 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 13 mg (0.030 mmol, 8% yield) of the title compound was obtained. 1H NMR (400 MHz, Methanol- d_4) δ 7.67 (d, J = 2.5 Hz, 1H), 7.64 (d, J = 2.5 Hz, 1H), 7.53 (d, J = 1.6 Hz, 1H), 6.83 (d, J = 1.6 Hz, 1H), 4.12 – 4.05 (m, 2H), 3.98 – 3.90 (m, 1H), 3.78 – 3.66 (m, 2H), 2.01 – 1.92 (m, 1H), 1.87 – 1.76 (m, 1H), 1.66 – 1.55 (m, 1H), 1.49 – 1.39 (m, 1H). LCMS t_R = 0.824 min, m/z = 436.2, 437.3 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-N-(1-(cyclobutanecarbonyl)-1H-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2o)

Step A: 1-(Cyclobutanecarbonyl)-4-nitro-1H-imidazole (15o): Cyclobutanecarbonyl chloride (210 mg, 1.77 mmol, 1 eq) was dissolved in MeCN at 5 M. Then, 4-nitroimidazole (200 mg, 1.77 mmol, 1 eq) and Et_3N (250 μ L, 1.77 mmol, 1 eq) were added. The reaction mixture was stirred for 16 h at 75 °C. Upon cooling to room temperature, the mixture was filtered and washed with EtOAc. The solvent was dried over a phase separator and the solvent removed under vacuum. The crude was purified using ISCO flash chromatography, 125 mg (0.34 mmol, 19% yield) of the title compound was obtained. LCMS t_R = 0.987 min, m/z = does not ionize by ESI.

Step B: 1-(1-(Cyclobutanecarbonyl)-1H-imidazol-4-aminium chloride (5o): 1-

Cyclobutanecarbonyl-4-nitro-1H-imidazole (125 mg, 0.34 mmol) was reacted following *General Procedure 3*. Crude material (70 mg) was taken forward. LCMS t_R = 0.347 min, m/z = 166.3 $[M+H]^+$.

Step C: 5-Bromo-3-chloro-N-(1-(cyclobutanecarbonyl-1H-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-(Cyclobutanecarbonyl)-1H-imidazol-4-aminium chloride (70 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 3 mg (0.007 mmol, 2% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform-*d*) δ 7.94 (d, J = 2.4 Hz, 1H), 7.90 (d, J = 1.5 Hz, 1H), 7.76 (d, J = 2.4 Hz, J = 1.5 Hz, 1H), 7.69 (s, 1H), 7.55 (s, 1H), 3.14 (t, J = 8.4 Hz, 1H), 2.39 – 2.30 (m, 2H), 2.27 – 2.17 (m, 2H), 2.02 (s, 1H), 1.96 – 1.88 (m, 1H). LCMS t_R = 1.020 min, m/z = 434.1, 435.2 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-N-(1-(cyclopentanecarbonyl)-1H-imidazol-4-yl)-2-hydroxybenzenesulfonamide (2p)

Step A: 1-(Cyclopentanecarbonyl)-4-nitro-1H-imidazole (15p): Cyclopentanecarbonyl chloride (210 mg, 1.77 mmol, 1 eq) was dissolved in MeCN at 5 M. Then, 4-nitroimidazole (200 mg, 1.77 mmol, 1 eq) and Et_3N (250 μ L, 1.77 mmol, 1 eq) were added. The reaction mixture was stirred for 16 h at 75 °C. Upon cooling to room temperature, the mixture was filtered and washed with EtOAc. The solvent was dried over a phase separator and the solvent removed under vacuum. The crude was purified using ISCO flash chromatography. 41 mg (0.055 mmol, 3% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform-*d*) δ 8.26 (d, J = 1.7 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 3.46 – 3.34 (m, 1H), 2.13 – 1.98 (m, 4H), 1.86 – 1.71 (m, 5H).

Step B: 1-(1-(Cyclopentanecarbonyl)-1H-imidazol-4-aminium chloride (5p): 1-

Cyclopentanecarbonyl-4-nitro-1H-imidazole (41 mg, 0.55 mmol) was reacted following *General Procedure 3*. The crude material (48 mg) was taken forward. LCMS t_R = 0.279 min, m/z = 198.4 $[M+NH_4]^+$.

Step C: 5-Bromo-3-chloro-N-(1-(cyclopentanecarbonyl)-1H-imidazol-4-yl)-2-

hydroxybenzenesulfonamide: 1-(Cyclopentanecarbonyl)-1H-imidazol-4-aminium chloride (48 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 4 mg (0.009 mmol, 33% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform-*d*) δ 8.02 (br s, 1H), 7.95 (t, J = 2.4 Hz, 2H), 7.76 (d, J = 2.4 Hz, 1H), 7.69 (d, J = 1.6 Hz, 1H), 2.74 – 2.68 (m, 1H), 1.93 (d, J = 8.2 Hz, 2H), 1.88 – 1.69 (m, 4H), 1.66 – 1.56 (m, 2H). LCMS t_R = 1.068 min, m/z = 448.1, 449.3 $[M+H]^+$; Purity (AUC) 95%.

Table 2 Examples**5-Bromo-3-chloro-N-(1-cyclopentyl-1H-1,2,4-triazol-3-yl)-2-hydroxybenzenesulfonamide (3a)**

Step A: 1-Cyclopentyl-3-nitro-1H-1,2,4-triazole: 3-Nitro-1,2,4-triazole (100 mg, 0.88 mmol) was reacted with bromocyclopentane (1.14 mmol) following *General Procedure 2*.

After purification, 120 mg (0.66 mmol, 75% yield) of the title compound was obtained. LCMS t_R = 0.800 min, m/z = 283.3 $[M+H]^+$.

Step B: 1-Cyclopentyl-1*H*-1,2,4-triazole-3-aminium chloride (19a): 1-Cyclopentyl-3-nitro-1*H*-1,2,4-triazole (120 mg, 0.66 mmol) was reacted following *General Procedure 3*. The crude material (124 mg) was taken forward. LCMS t_R = 0.089 min, m/z = 153.3 $[M+H]^+$.

Step C: 5-Bromo-3-chloro-*N*-(1-cyclopentyl-1*H*-1,2,4-triazol-3-yl)-2-hydroxybenzenesulfonamide: 1-Cyclopentyl-1*H*-1,2,4-triazole-3-aminium chloride (50 mg, 0.27 mmol) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 33 mg (0.030 mmol, 20% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform-*d*) δ 7.95 (s, 1H), 7.87 (d, J = 2.4 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 4.60 (t, J = 6.2 Hz, 1H), 2.19 – 2.12 (m, 2H), 2.00 – 1.85 (m, 4H), 1.77 – 1.69 (m, 2H). LCMS t_R = 1.038 min, m/z = 421.2, 423.1 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(5-cyclopentyl-1*H*-pyrazol-3-yl)-2-hydroxybenzenesulfonamide (3b)—5-Cyclopentyl-1*H*-pyrazol-3-amine (50 mg, 0.33 mmol) was reacted with bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General procedure 4*. After purification, 25 mg (0.059 mmol, 18% yield) of the title compound was obtained. ^{13}C NMR (101 MHz, Chloroform-*d*) δ 164.24, 151.42, 149.78, 139.14, 129.16, 127.28, 127.03, 110.52, 88.89, 39.16, 32.23, 25.38. 1H NMR (400 MHz, Chloroform-*d*) δ 7.84 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 5.32 (s, 1H), 2.95 (p, J = 8.0 Hz, 1H), 2.05 – 1.94 (m, 2H), 1.77 – 1.57 (m, 6H). LCMS t_R = 1.232 min, m/z = 420.2, 422.2 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclopentyl-1*H*-pyrazol-3-yl)-2-hydroxybenzenesulfonamide (3c)—1-Cyclopentyl-1*H*-pyrazol-3-amine (30 mg, 0.20 mmol) was reacted with bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General procedure 4*. After purification, 71 mg (0.17 mmol, 84% yield) of the title compound was obtained. ^{13}C NMR (101 MHz, Chloroform-*d*) δ 150.50, 143.65, 137.57, 129.94, 129.36, 125.81, 124.57, 111.23, 99.09, 63.42, 32.93, 24.05. 1H NMR (400 MHz, Chloroform-*d*) δ 7.61 (d, J = 2.4 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.32 (d, J = 2.4 Hz, 1H), 6.15 (d, J = 2.4 Hz, 1H), 4.63 – 4.52 (m, 1H), 2.16 – 2.04 (m, 2H), 1.90 – 1.61 (m, 6H). LCMS t_R = 1.118 min, m/z = 420.1, 422.2 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclopentyl-1*H*-pyrazol-4-yl)-2-hydroxybenzenesulfonamide (3d)—1-Cyclopentyl-1*H*-pyrazol-4-aminium chloride (30 mg, 0.15 mmol) was reacted with bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General procedure 4*. After purification, 38 mg (0.090 mmol, 59% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform-*d*) δ 7.68 (d, J = 2.3 Hz, 1H), 7.60 (d, J = 2.3 Hz, 1H), 7.37 (d, J = 0.8 Hz, 1H), 7.22 (d, J = 0.8 Hz, 1H), 6.45 (s, 1H), 4.65 – 4.54 (m, 1H), 2.19 – 2.08 (m, 2H), 1.97 – 1.86 (m, 2H), 1.86 – 1.65 (m, 4H). LCMS t_R = 1.056 min, m/z = 420.2, 422.2 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(2-cyclopentylthiazol-5-yl)-2-hydroxybenzenesulfonamide (3e)

Step A: *tert*-Butyl (2-(cyclopent-1-en-1-yl)thiazol-5-yl)carbamate: *tert*-Butyl (2-bromothiazol-5-yl)carbamate (200 mg, 0.716 mmol) was reacted with cyclopent-1-enylboronic acid (0.860 mmol) following *General Procedure 12*. After purification, 157 mg (0.589 mmol, 82% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.46 (br s, 1H), 7.25 (s, 1H), 6.33 (t, *J* = 2.3 Hz, 1H), 2.83 – 2.73 (m, 2H), 2.58 – 2.48 (m, 2H), 2.00 (p, *J* = 7.5 Hz, 2H). LCMS *t*_R = 0.956 min, *m/z* = 267.3 [M+H]⁺.

Step B: 2-(Cyclopent-1-en-1-yl)thiazol-5-aminium chloride: *tert*-Butyl (2-(cyclopent-1-en-1-yl)thiazol-5-yl)carbamate (30 mg, 0.11 mmol) was reacted following *General Procedure 13*. The crude material (75 mg) was taken forward. ¹H NMR (400 MHz, Methanol-*d*₄) δ 6.78 (s, 1H), 3.76 – 3.55 (m, 1H), 2.78 (d, *J* = 6.5 Hz, 2H), 2.69 – 2.61 (m, 2H), 2.11 (p, *J* = 7.6 Hz, 2H).

Step C: 2-Cyclopentylthiazol-5-aminium chloride (19f): 2-(Cyclopent-1-en-1-yl)thiazol-5-aminium chloride (75 mg, crude) was reacted following *General Procedure 3*. The crude material (50 mg) was taken forward. LCMS *t*_R = 0.214 min, *m/z* = 169.3 [M+H]⁺.

Step D: 5-Bromo-3-chloro-*N*-(2-cyclopentylthiazol-5-yl)-2-hydroxybenzenesulfonamide: 2-Cyclopentylthiazol-5-aminium chloride (50 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 3 mg (0.007 mmol, 1% yield) of the title compound was obtained. ¹³C NMR (101 MHz, Chloroform-*d*) δ 176.86, 149.80, 138.00, 137.78, 130.72, 130.46, 124.92, 124.44, 112.06, 44.51, 34.17, 25.50. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.71 (d, *J* = 2.4 Hz, 1H), 7.68 (d, *J* = 2.4 Hz, 1H), 7.33 (s, 1H), 3.41 – 3.29 (m, 1H), 2.20 – 2.12 (m, 2H), 1.83 – 1.76 (m, 2H), 1.76 – 1.71 (m, 2H), 1.71 – 1.65 (m, 2H). LCMS *t*_R = 1.088 min, *m/z* = 437.1, 439.2 [M+H]⁺; Purity (AUC) 95%.

***N*-(Benzo[*d*]thiazol-2-yl)-5-bromo-3-chloro-2-hydroxybenzenesulfonamide (3f)** —Benzothiazol-2-amine (50 mg, 0.33 mmol) was reacted with bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General procedure 4*. After purification, 9.0 mg (0.021 mmol, 6% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.82 (d, *J* = 2.4 Hz, 1H), 7.64 (d, *J* = 2.4 Hz, 1H), 7.61 (d, *J* = 7.9 Hz, 1H), 7.49 – 7.42 (m, 2H), 7.37 – 7.31 (m, 1H). LCMS *t*_R = 1.099 min, *m/z* = 419.1, 422.2 [M+H]⁺; Purity (AUC) 95%.

Table 3 Examples

5-Bromo-3-chloro-*N*-(1-cyclopentyl-2-methyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (4)

Step A: 1-Cyclopentyl-2-methyl-4-nitro-1*H*-imidazole: 2-Methyl-4-nitro-1*H*-imidazole (800 mg, 6.29 mmol) was reacted with bromocyclopentane (8.18 mmol) following *General Procedure 2*. After purification, 675 mg (3.46 mmol, 55% yield) of the title compound was obtained. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.72 (s, 1H), 4.46 (p, *J* = 7.1 Hz, 1H), 2.46

(s, 3H), 2.30 – 2.18 (m, 2H), 1.99 – 1.86 (m, 2H), 1.85 – 1.73 (m, 4H). LCMS t_R = 0.695 min, m/z = 196.3 $[M+H]^+$.

Step B: 1-Cyclopentyl-2-methyl-1H-imidazol-4-aminium chloride (22): Cyclopentyl-2-methyl-4-nitro-1H-imidazole (21.0 mg, 0.057 mmol) was reacted following *General Procedure 3*. The crude material (30 mg) was taken forward. LCMS t_R = 0.280 min, m/z = 166.4 $[M+H]^+$.

Step C: 5-Bromo-3-chloro-N-(Cyclopentyl-2-methyl-1H-imidazol-4-yl)-2-hydroxybenzenesulfonamide: 1-Cyclopentyl-2-methyl-1H-imidazol-4-aminium chloride (30 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 6 mg (0.014 mmol, 24%) of the title compound was obtained. 1H NMR (400 MHz, Chloroform- d) δ 7.72 (d, J = 2.4 Hz, 1H), 7.65 (d, J = 2.4 Hz, 1H), 6.93 (s, 1H), 4.47 (p, J = 7.2 Hz, 1H), 2.55 (s, 3H), 2.27 – 2.20 (m, 6H), 1.99 – 1.89 (m, 6H), 1.87 – 1.78 (m, 7H). LCMS t_R = 0.843 min, m/z = 434.2, 435.2 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-N-(1-cyclopentyl-2-ethyl-1H-imidazol-4-yl)-2-hydroxybenzenesulfonamide (5)

Step A: 2-Bromo-1-cyclopentyl-4-nitro-1H-imidazole: 2-Bromo-4-nitro-1H-imidazole (700 mg, 3.65 mmol) was reacted with bromocyclopentane (4.74 mmol) following *General Procedure 2*. After purification, 691 mg (2.65 mmol, 72% yield) of the title compound was obtained. 1H NMR (400 MHz, Methanol- d_4) δ 8.30 (s, 1H), 4.79 – 4.67 (m, 1H), 2.34 – 2.21 (m, 2H), 1.97 – 1.85 (m, 4H), 1.85 – 1.77 (m, 1H), 1.77 – 1.73 (m, 1H). LCMS t_R = 0.837 min, m/z = 260.1, 262.1 $[M+H]^+$.

Step B: 1-Cyclopentyl-4-nitro-2-vinyl-1H-imidazole (24): In a vial, 100 mg (0.38 mmol, 1 eq) of 2-bromo-1-cyclopentyl-4-nitro-1H-imidazole was added with 3.1:0.700 mL of 1,4-dioxane:H₂O. The solution was degassed with Ar for 10 min. Then, 44 mg (0.04 mmol, 0.10 eq) of Pd(PPh₃)₄, 65 mg (0.42 mmol, 1.1 eq) of vinyl boronic pinacol ester, and 376 mg (1.15 mmol, 3 eq) of Cs₂CO₃ were added. The reaction mixture was stirred at 135 °C for 36 hours. Water was added and extracted with DCM. The organic phase was dried over a phase separator and the solvent was removed under vacuum. The crude was purified using ISCO flash chromatography. 60 mg (0.20 mmol, 53% yield) of the title compound was obtained. 1H NMR (400 MHz, Chloroform- d) δ 7.74 (s, 1H), 6.59 (dd, J = 17.1, 11.1 Hz, 1H), 6.36 (dd, J = 17.1, 1.4 Hz, 1H), 5.58 (dd, J = 11.0, 1.4 Hz, 1H), 4.65 – 4.54 (m, 1H), 2.24 – 2.17 (m, 2H), 1.89 – 1.73 (m, 6H). LCMS t_R = 0.748 min, m/z = 208.3 $[M+H]^+$.

Step C: 1-Cyclopentyl-2-ethyl-1H-imidazol-4-aminium chloride (25): 1-Cyclopentyl-4-nitro-2-vinyl-1H-imidazole (50 mg, 0.21 mmol) was reacted following *General Procedure 3*. The crude material (52 mg) was taken forward. LCMS t_R = 0.092 min, m/z = 180.3 $[M+H]^+$.

Step D: 5-Bromo-3-chloro-N-(1-cyclopentyl-2-ethyl-1H-imidazol-4-yl)-2-hydroxybenzenesulfonamide: 1-Cyclopentyl-2-methyl-1H-imidazol-4-aminium chloride (52 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride

following *General Procedure 4*. After purification, 23 mg (0.096 mmol, 48% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.68 (d, J = 2.3 Hz, 1H), 7.54 (d, J = 2.3 Hz, 1H), 6.42 (s, 1H), 4.43 (p, J = 7.2 Hz, 1H), 2.96 (q, J = 7.3 Hz, 2H), 2.21 – 2.10 (m, 2H), 1.91 (s, 2H), 1.84 – 1.70 (m, 4H), 1.30 (t, J = 7.3 Hz, 3H). LCMS t_R = 0.901 min, m/z = 448.2, 450.2 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

Ethyl 4-((5-bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1H-imidazole-2-carboxylate (6)

Step A: Ethyl 1-cyclopentyl-4-nitro-1H-imidazole-2-carboxylate (28): Ethyl 4-nitro-1H-imidazole-2-carboxylate (300 mg, 1.62 mmol) was reacted with bromocyclopentane (1.94 mmol) following *General Procedure 2*. After purification, 252 mg (0.995 mmol, 61% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.93 (s, 1H), 5.49 (p, J = 7.1 Hz, 2H), 4.41 – 4.30 (m, 2H), 2.32 – 2.18 (m, 2H), 1.86 – 1.69 (m, 6H), 1.38 – 1.29 (m, 3H). LCMS t_R = 0.873 min, m/z = 254.2 $[\text{M}+\text{H}]^+$.

Step B: Ethyl 1-cyclopentyl-1H-imidazole-4-aminium chloride-2-carboxylate

(29): Ethyl 1-cyclopentyl-4-nitro-1H-imidazole-2-carboxylate (150 mg, 0.592 mmol) was reacted following *General Procedure 3*. The crude material (159 mg) was taken forward. LCMS t_R = 0.625 min, m/z = 224.3 $[\text{M}+\text{H}]^+$.

Step C: Ethyl 4-((5-bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1H-imidazole-2-carboxylate:

Ethyl 1-cyclopentyl-1H-imidazole-4-aminium chloride-2-carboxylate (159 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl following *General Procedure 4*. After purification, 76.5 mg (0.155 mmol, 25% yield) of the title compound was obtained. ^{13}C NMR (101 MHz, Chloroform-*d*) δ 158.06, 150.81, 137.30, 134.62, 132.77, 130.20, 127.61, 124.45, 112.35, 110.73, 62.02, 59.29, 33.97, 24.15, 13.85. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.70 (d, J = 2.4 Hz, 1H), 7.56 (d, J = 2.4 Hz, 1H), 7.14 (s, 1H), 5.61 – 5.51 (m, 1H), 4.23 (q, J = 7.1 Hz, 2H), 2.30 – 2.19 (m, 2H), 1.90 – 1.71 (m, 6H), 1.15 (t, J = 7.1 Hz, 3H). LCMS t_R = 1.128 min, m/z = 492.2, 493.3 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

4-((5-Bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1H-imidazole-2-carboxylic acid (7)—Ethyl 4-((5-bromo-3-chloro-2-

hydroxyphenyl)sulfonamido)-1-cyclopentyl-1H-imidazole-2-carboxylate (27 mg, 0.047 mmol) was reacted following *General Procedure 7*. After purification, 6 mg (0.013 mmol, 27% yield) of the title compound was obtained. ^{13}C NMR (101 MHz, Chloroform-*d*) δ 158.06, 150.81, 137.30, 134.62, 132.77, 130.20, 127.61, 124.45, 112.35, 110.73, 62.02, 59.29, 33.97, 24.15, 13.85. ^1H NMR (400 MHz, Methanol-*d*₄) δ 7.76 (d, J = 2.4 Hz, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.14 (s, 1H), 5.59 (p, J = 6.7 Hz, 1H), 2.25 – 2.15 (m, 2H), 1.87 – 1.80 (m, 2H), 1.80 – 1.69 (m, 4H). LCMS t_R = 1.552 min, m/z = 463.8, 464.8 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

4-((5-Bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-N-methyl-1H-imidazole-2-carboxamide (8) 4-((5-Bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1H-imidazole-2-carboxylic acid (20 mg, (0.047 mmol) was reacted with

methylamine following *General Procedure 8*. After purification, 11 mg (0.023 mmol, 49% yield) of the title compound was obtained. ^{13}C NMR (151 MHz, Methanol- d_4) δ 161.27, 152.28, 137.88, 137.21, 135.76, 131.93, 129.35, 125.49, 112.65, 111.04, 59.69, 34.69, 25.97, 24.98. ^1H NMR (600 MHz, Methanol- d_4) δ 7.74 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 2.4 Hz, 1H), 6.99 (s, 1H), 5.65 (p, J = 7.3 Hz, 1H), 2.83 (s, 3H), 2.18 – 2.11 (m, 2H), 1.85 – 1.76 (m, 2H), 1.76 – 1.65 (m, 4H). LCMS t_R = 1.027 min, m/z = 477.2, 478.3 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclopentyl-2-(4-(pyrrolidin-3-yl)piperidine-1-carbonyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (9)

Step A: *tert*-Butyl 3-(1-(4-((5-bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1*H*-imidazole-2-carboxylic (33 mg, 0.071 mmol, 1 eq) was mixed with DIPEA (0.21 mmol, 3 eq) and *tert*-butyl 3-(piperazin-1-yl)pyrrolidine-1-carboxylate (0.14 mmol, 2 eq). The mixture was diluted in DCM (0.29 M) and then HATU (0.082 mmol, 1.15 eq) was added. The reaction mixture was stirred at room temperature for 17 hours, then diluted with water and extracted with EtOAc. The organic phase was dried using a filter separator and the solvent was removed under vacuum. The crude material (97 mg) was taken forward. LCMS (Method B) t_R = 0.975 min, m/z = 701.5, 702.5 min $[\text{M}+\text{H}]^+$.

Step B: 5-Bromo-3-chloro-*N*-(1-cyclopentyl-2-(4-(pyrrolidin-3-yl)piperidine-1-carbonyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide: *tert*-Butyl 3-(1-(4-((5-bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1*H*-imidazole-2-carboxyl)piperidin-4-yl)pyrrolidine-1-carboxylate (50 mg, crude) was reacted following *General Procedure 13*. After purification, 7.0 mg (0.87 mmol, 15% yield) the title compound was obtained. ^1H NMR (400 MHz, DMSO- d_6) δ 8.88 (br s, 1H), 7.40 (d, J = 2.7 Hz, 1H), 7.21 (d, J = 2.7 Hz, 1H), 6.98 (s, 1H),

4.78 (p, J = 7.3 Hz, 1H), 3.54 (br s, 2H), 3.43 (br s, 2H), 3.37 – 3.24 (m, 3H), 3.20 – 3.09 (m, 1H), 3.05 – 2.88 (m, 2H), 2.46 – 2.20 (m, 4H), 2.12 – 1.97 (m, 3H), 1.86 – 1.52 (m, 7H). LCMS (Method B) t_R = 0.838 min, m/z = 601.3, 603.3 $[\text{M}+\text{H}]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclopentyl-2-(4-(2-methoxyethyl)piperazine-1-carbonyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (10)—4-((5-Bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1*H*-imidazole-2-carboxylic acid (40 mg, 0.086 mmol, 1 eq) was mixed with DIPEA (0.26 mmol, 3 eq) and 1-(2-methoxyethyl)piperazine (0.17 mmol, 2 eq). The mixture was diluted in DCM (0.29 M) and then HATU (0.099 mmol, 1.15 eq) was added. The reaction mixture was stirred at room temperature for 17 hours, then diluted with water and extracted with EtOAc. The organic phase was dried using a filter separator and the solvent was removed under vacuum. The crude was purified using preparative HPLC, 16 mg (0.086 mmol, 31% yield) of the title compound was obtained. ^1H NMR (400 MHz, Methanol- d_4) δ 7.80 (d, J = 2.4 Hz, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.14 (s, 1H), 4.98 (p, J = 7.3 Hz, 1H), 3.76 (t, J = 4.9 Hz, 2H), 3.44 (s,

3H), 3.47–3.20 (br s, 10H), 2.24 – 2.15 (m, 2H), 1.91 – 1.80 (m, 2H), 1.73 (s, 4H). LCMS (Method B) t_R = 0.879 min, m/z = 590.3, 592.3 $[M+H]^+$; Purity (AUC) 95%.

5-Bromo-3-chloro-*N*-(1-cyclopentyl-2-(2,6-diazaspiro[3.3]heptane-2-carbonyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide (11)

Step A: *tert*-Butyl 6-(4-((5-bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1*H*-imidazole-2-carboxylate)-1-cyclopentyl-1*H*-imidazole-2-carboxylic acid (40 mg, 0.086 mmol, 1 eq) was mixed with DIPEA (0.26 mmol, 3 eq) and *tert*-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (0.17 mmol, 2 eq). The mixture was diluted in DCM (0.29 M) and then HATU (0.099 mmol, 1.15 eq) was added. The reaction mixture was stirred at room temperature for 17 hours, then diluted with water and extracted with EtOAc. The organic phase was dried using a filter separator and the solvent was removed under vacuum. The crude material (98 mg) was taken forward. LCMS (Method B) t_R = 1.130 min, m/z = 544.3, 546.3 $[M+H]^+$.

Step B: 5-Bromo-3-chloro-*N*-(1-cyclopentyl-2-(2,6-diazaspiro[3.3]heptane-2-carbonyl)-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide: *tert*-Butyl 6-(4-((5-bromo-3-chloro-2-hydroxyphenyl)sulfonamido)-1-cyclopentyl-1*H*-imidazole-2-carboxylate)-1-cyclopentyl-1*H*-imidazole-2-carboxylate (98 mg, crude) was reacted following *General Procedure 13*. After purification, 7.0 mg (0.87 mmol, 15% yield) of the title compound was obtained. ^{13}C NMR (151 MHz, DMSO- d_6) δ 159.2, 136.3, 136.0, 134.6, 128.7, 127.7, 126.5, 110.9, 63.2, 57.9, 52.0, 51.3,

47.8, 46.7, 44.5, 41.8, 40.5, 33.7, 28.1, 24.0. ^1H NMR (600 MHz, DMSO- d_6) δ 8.88 (s, 2H), 7.42 (s, 1H), 7.23 (s, 1H), 6.99 (s, 1H), 4.78 (p, J = 7.5 Hz, 1H), 3.54 (d, J = 5.2 Hz, 2H), 3.43 (s, 2H), 3.36 – 3.26 (m, 3H), 3.18 – 3.12 (m, 1H), 3.00 (dd, J = 11.4, 7.6 Hz, 1H), 2.97 – 2.89 (m, 1H), 2.47 – 2.37 (m, 2H), 2.37 – 2.30 (m, 1H), 2.26 (dt, J = 11.0, 5.0 Hz, 1H), 2.11 – 1.99 (m, 3H), 1.82 – 1.70 (m, 3H), 1.67 – 1.54 (m, 4H). LCMS (Method B) t_R = 0.851 min, m/z = 544.3, 546.3 $[M+H]^+$; Purity (AUC) 95%.

1-Cyclopentyl-2-(methylsulfonyl)-4-nitro-1*H*-imidazole (12)

Step A: 1-Cyclopentyl-2-(methylthio)-4-nitro-1*H*-imidazole: 2-Bromo-1-cyclopentyl-4-nitro-1*H*-imidazole (500 mg, 1.92 mmol) was reacted with sodium methanethiolate following *General Procedure 9*. After purification, 124 mg (0.55 mmol, 29% yield) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform- d) δ 7.76 (s, 1H), 4.50 – 4.40 (m, 1H), 2.66 (s, 3H), 2.28 – 2.08 (m, 2H), 1.90 – 1.67 (m, 6H). LCMS t_R = 0.881 min, m/z = 228.3 $[M+H]^+$.

Step B: 1-Cyclopentyl-2-(methylsulfonyl)-4-nitro-1*H*-imidazole (26): 1-Cyclopentyl-2-(methylthio)-4-nitro-1*H*-imidazole (124 mg, 0.55 mmol) was reacted following *General Procedure 10*. After purification, 142 mg (0.55 mmol, quant.) of the title compound was obtained. ^1H NMR (400 MHz, Chloroform- d) δ 7.92 (s, 1H), 5.33 – 5.22 (m, 1H), 3.47 (s, 3H), 2.41 – 2.30 (m, 2H), 1.93 – 1.74 (m, 6H). LCMS t_R = 0.763 min, m/z = 260.2 $[M+H]^+$.

Step C: 1-Cyclopentyl-2-(methylsulfonyl)-1*H*-imidazole-4-aminium chloride (27): 1-Cyclopentyl-2-(methylsulfonyl)-4-nitro-1*H*-imidazole (30 mg, 0.13 mmol) was reacted following *General Procedure 3*. The crude material (25 mg) was taken forward. LCMS t_R = 0.186 min, m/z = 230.3 $[M+H]^+$.

Step D: 5-Bromo-3-chloro-*N*-(1-(cyclobutylmethyl)-2-methyl-1*H*-imidazol-4-yl)-2-hydroxybenzenesulfonamide: 1-Cyclopentyl-2-(methylsulfonyl)-1*H*-imidazole-4-aminium chloride (25 mg, crude) was reacted with 5-bromo-3-chloro-2-hydroxybenzenesulfonyl chloride following *General Procedure 4*. After purification, 13 mg (0.026 mmol, 20% yield) of the title compound was obtained. ^{13}C NMR (151 MHz, Chloroform-*d*) δ 149.87, 140.40, 137.65, 133.70, 130.06, 125.71, 124.36, 112.89, 111.50, 59.22, 43.21, 34.21, 24.17. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.88 (d, J = 2.3 Hz, 2H), 7.47 (s, 1H), 5.47 (p, J = 6.8, 6.4 Hz, 1H), 3.44 (s, 3H), 2.56 – 2.45 (m, 2H), 2.10 – 2.04 (m, 2H), 2.04 – 1.92 (m, 4H). LCMS t_R = 1.052 min, m/z = 498.2, 500.1 $[M+H]^+$; Purity (AUC) 95%.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors thank Qi Sun and DeMarco Camper for their contributions to this series of compounds during this project. This work was supported by a grant from the NIH/NCI (CA200709 to W.P.T). This work was also supported by grants from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation [to W.P.T. and S.W.F.], The TJ Martell Foundation [to W.P.T. and S.W.F.], the Edward P. Evans Foundation [to W.P.T.], Alex's Lemonade Stand Foundation [to W.P.T.], St. Baldrick's Foundation [to W.P.T.], CA236733 [to S.W.F. and W.P.T.], and CA211305 [to L. R. T.]

Abbreviations Used

WDR5	WD-repeat protein 5
WBM	WDR5-binding motif
WIN	WDR5-interacting site
RBBP5	retinoblastoma binding protein 5
KANSL2	KAT8 Regulatory NSL Complex Subunit 2
MLL	mixed lineage leukemia
PDAC	pancreatic ductal adenocarcinoma
HMT	histone methyl transferase
HTS	high-throughput screen
FPA	fluorescence polarization assay
FITC	fluorescein isothiocyanate
Co-IP	Co-immunoprecipitation

ChIP Chromatin immunoprecipitation

REFERENCES

- (1). Campaner S; Amati B Two Sides of the Myc-Induced DNA Damage Response: From Tumor Suppression to Tumor Maintenance. *Cell Div.* 2012, 7 (1), 6 10.1186/1747-1028-7-6. [PubMed: 22373487]
- (2). Henriksson M; Luscher B Proteins of the MYC Network: Essential Regulators of Cell Growth and Differentiation. *Adv. Cancer Research* 1996, 68, 109–182. 10.1016/s0065-230x(08)60353-x.
- (3). Dang CV Review MYC on the Path to Cancer. *Cell* 2012, 149 (1), 22–35. 10.1016/j.cell.2012.03.003. [PubMed: 22464321]
- (4). Dalla-Favera R; Bregni M; Eriksont J; Patterson D; Gallo RC; Crocet CM Human CMyc Onc Gene is Located on the Region of Chromosome 8 that is Translocated in Burkitt Lymphoma Cells. *Proc. Natl. Acad. Sci* 1982, 79 (December), 7824–7827. 10.1073/pnas.79.24.7824. [PubMed: 6961453]
- (5). Tansey WP Mammalian MYC Proteins and Cancer. *New J. Sci* 2014, 1–27. 10.1155/2014/757534.
- (6). Dang CV C-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism. *Mol. Cell. Biol* 1999, 19 (1), 1–11. 10.1128/MCB.19.1.1. [PubMed: 9858526]
- (7). Chrzan P; Skokowski J; Karmolinski A; Pawelczyk T Amplification of C- Myc Gene and Overexpression of c-Myc Protein in Breast Cancer and Adjacent Non-Neoplastic Tissue. *Clin. Biochem* 2001, 34, 557–562. 10.1016/S0009-9120(01)00260-0. [PubMed: 11738392]
- (8). Prochownik EV; Vogt PK Therapeutic Targeting of Myc. *Genes Cancer* 2010, 1 (6), 650–659. 10.1177/1947601910377494. [PubMed: 21132100]
- (9). Goga A; Yang D; Tward AD; Morgan DO; Bishop JM Inhibition of CDK1 as a Potential Therapy for Tumors Over-Expressing MYC. *Nat. Med* 2007, 13 (7). 10.1038/nm1606.
- (10). Yu C; Niu X; Jin F; Liu Z; Jin C; Lai L Structure-Based Inhibitor Design for the Intrinsically Disordered Protein c-Myc. *Sci. Rep* 2016, 6, 1–11. 10.1038/srep22298. [PubMed: 28442746]
- (11). Thomas LR; Wang Q; Grieb BC; Phan J; Foshage AM; Sun Q; Olejniczak ET; Clark T; Dey S; Lorey S; Alicie B; Howard GC; Cawthon B; Ess KC; Eischen CM; Zhao Z; Fesik SW; Tansey WP Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC. *Mol. Cell* 2015, 58 (3), 440–452. 10.1016/j.molcel.2015.02.028. [PubMed: 25818646]
- (12). Stirnimann C; Petsalaki E; Russell R; Muller C WD40 Proteins Propel Cellular Networks. *Trends Biochem. Sci* 2010, 35 (10), 565–574. 10.1016/j.tibs.2010.04.003. [PubMed: 20451393]
- (13). Guarnaccia A; Tansey W Moonlighting with WDR5: A Cellular Multitasker. *J. Clin. Med* 2018, 7 (2), 1–17. 10.3390/jcm7020021.
- (14). Thomas LR; Adams CM; Wang J; Weissmiller AM; Creighton J; Lorey SL; Liu Q; Fesik SW; Eischen CM; Tansey WP Interaction of the Oncoprotein Transcription Factor MYC with its Chromatin Cofactor WDR5 is Essential for Tumor Maintenance. *Proc. Natl. Acad. Sci. U. S. A* 2019, 116 (50), 1–9. 10.1073/pnas.1910391116.
- (15). Carugo A; Seth S; Heffernan TP In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. *Cell Rep* 2016, 16, 133–147. 10.1016/j.celrep.2016.05.063. [PubMed: 27320920]
- (16). Macdonald JD; Chacón Simon S; Han C; Wang F; Shaw JG; Howes JE; Sai J; Yuh JP; Camper D; Alicie BM; Alvarado J; Nikhar S; Payne W; Aho ER; Bauer JA; Zhao B; Phan J; Thomas LR; Rossanese OW; Tansey WP; Waterson AG; Stauffer SR; Fesik SW Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5–MYC Protein–Protein Interaction. *J. Med. Chem* 2019, 62 (24), 11232–11259. 10.1021/acs.jmedchem.9b01411. [PubMed: 31724864]
- (17). Ionescu C Pathways of Biotransformation - Phase II Reactions In Drug Metabolism: Current Concepts; Caira MR, Eds.; Springer: Dordrecht, 2005; pp 129–170. 10.1007/1-4020-4142-X_3.
- (18). Rietjens IMCM; Besten C. Den; Hanzlik RP; Van Bladeren PJ Cytochrome P450-Catalyzed Oxidation of Halobenzene Derivatives. *Chem. Res. Toxicol* 1997, 10 (6), 629–635. 10.1021/tx9601061. [PubMed: 9208168]

- (19). Shuker SB; Hajduk PJ; Meadows RP; Fesik SW Discovering High-Affinity Ligands for Proteins: SAR by NMR. *Science* 1996, 274 (5292), 1531–1534. 10.1126/science.274.5292.1531. [PubMed: 8929414]
- (20). Scott DE; Coyne AG; Hudson SA; Abell C Fragment-Based Approaches in Drug Discovery and Chemical Biology. *Biochemistry* 2012, 51 (25), 4990–5003. 10.1021/bi3005126. [PubMed: 22697260]
- (21). Harner MJ; Frank AO; Fesik SW Fragment-Based Drug Discovery Using NMR Spectroscopy. *J. Biomol. NMR* 2013, 56 (2), 65–75. 10.1007/s10858-013-9740-z. [PubMed: 23686385]
- (22). Ichihara O; Barker J; Law RJ; Whittaker M Compound Design by Fragment-Linking. *Mol. Inform* 2011, 30 (4), 298–306. 10.1002/minf.201000174. [PubMed: 27466947]
- (23). Southall SM; Wong PS; Odho Z; Roe SM; Wilson JR Structural Basis for the Requirement of Additional Factors for MLL1 SET Domain Activity and Recognition of Epigenetic Marks. *Mol. Cell* 2009, 33 (2), 181–191. 10.1016/j.molcel.2008.12.029. [PubMed: 19187761]
- (24). Dias J; Van Nguyen N; Georgiev P; Gaub A; Brettschneider J; Cusack S; Kadlec J; Akhtar A Structural Analysis of the KANSL1/WDR5/ KANSL2 Complex Reveals That WDR5 Is Required for Efficient Assembly and Chromatin Targeting of the NSL Complex. *Genes Dev* 2014, 28 (9), 929–942. 10.1101/gad.240200.114. [PubMed: 24788516]
- (25). Avdic V; Zhang P; Lanouette S; Groulx A; Tremblay V; Brunzelle J; Couture JF Structural and Biochemical Insights into MLL1 Core Complex Assembly. *Structure* 2011, 19 (1), 101–108. 10.1016/j.str.2010.09.022. [PubMed: 21220120]
- (26). Hao C; Zhao F; Song H; Guo J; Li X; Jiang X; Huan R; Song S; Zhang Q; Wang R; Wang K; Pang Y; Liu T; Lu T; Huang W; Wang J; Lin B; He Z; Li H; Li F; Zhao D; Cheng M Structure-Based Design of 6-Chloro-4-Aminoquinazoline-2-Carboxamide Derivatives as Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors. *J. Med. Chem* 2018, 61 (1), 265–285. 10.1021/acs.jmedchem.7b01342. [PubMed: 29190083]
- (27). Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE Selective Inhibition of BET Bromodomains. *Nature* 2010, 468 (7327), 1067–1073. 10.1038/nature09504. [PubMed: 20871596]
- (28). Delmore JE; Issa GC; Lemieux ME; Rahl PB; Shi J; Jacobs HM; Kastiris E; Gilpatrick T; Paranal RM; Qi J; Chesi M; Schinzel AC; McKeown MR; Heffernan TP; Vakoc CR; Bergsagel PL; Ghobrial IM; Richardson PG; Young RA; Hahn WC; Anderson KC; Kung AL; Bradner JE; Mitsiades CS BET Bromodomain Inhibition as a Therapeutic Strategy to Target C-Myc. *Cell* 2011, 146 (6), 904–917. 10.1016/j.cell.2011.08.017. [PubMed: 21889194]
- (29). Mertz JA; Conery AR; Bryant BM; Sandy P; Balasubramanian S; Mele DA; Bergeron L; Sims RJ Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains. *Proc. Natl. Acad. Sci* 2011, 108 (40), 16669–16674. 10.1073/pnas.1108190108. [PubMed: 21949397]
- (30). Andrieu G; Belkina AC; Denis GV Clinical Trials for BET Inhibitors Run Ahead of the Science. *Drug Discov. Today Technol* 2016, 19, 45–50. 10.1016/j.ddtec.2016.06.004.
- (31). Chen H; Liu H; Qing G Targeting Oncogenic Myc as a Strategy for Cancer Treatment. *Signal Transduct. Target. Ther* 2018, 3 (1), 1–7. 10.1038/s41392-018-0008-7. [PubMed: 29527327]
- (32). Schanda P; Kupce E; Brutscher B SOFAST-HMQC Experiments for Recording 2D Heteronuclear Correlation Spectra of Proteins within Seconds. *J. Biomol. NMR* 2005, 33, 199–211. 10.1007/s10858-005-4425-x. [PubMed: 16341750]
- (33). Otwinowski Z; Minor W Processing of X-Ray Diffraction Data Collected in Oscillation Mode. *Methods Enzymol* 1997, 276, 307–326. 10.1016/S0076-6879(97)76066-X.
- (34). Winn MD; Ballard CC; Cowtan KD; Dodson EJ; Emsley P; Evans PR; Keegan RM; Krissinel EB; Leslie AGW; McCoy A; McNicholas SJ; Murshudov GN; Pannu NS; Potterton EA; Powell HR; Read RJ; Vagin A; Wilson KS Overview of the CCP4 Suite and Current Developments. *Acta Crystallogr. Sect. D Biol. Crystallogr* 2011, 67, 235–242. 10.1107/S0907444910045749. [PubMed: 21460441]
- (35). Adams PD; Grosse-Kunstleve RW; Hung LW; Ioerger TR; McCoy AJ; Moriarty NW; Read RJ; Sacchettini JC; Sauter NK; Terwilliger TC PHENIX: Building New Software for Automated

Crystallographic Structure Determination. Acta Crystallogr. Sec. D Biol. Crystallogr 2002; Vol. 58, pp 1948–1954. 10.1107/S0907444902016657.

- (36). Emsley P; Cowtan K Coot: Model-Building Tools for Molecular Graphics. Acta Crystallogr. Sec. D Biol. Crystallogr 2004, 60, 2126–2132. 10.1107/S0907444904019158.
- (37). Schrodinger LLC. The PyMOL Molecular Graphics System, Version 1.8. 2015.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.
Crystal structure of MbIIIb MYC peptide bound to WDR5 at the WBM (PDB: 4Y7R).

Figure 2.

A) Overlay of the HMQC spectra of apo-WDR5 (black) and WDR5 with unlabeled MYC peptide (red). B) Overlay of HMQC spectra of apo-WDR5 (black) and WDR5 with MYC site fragment hit **F2** (red). The shifts upon ligand (peptide or hit) binding are indicated.

Figure 3.
Representative MYC site fragment hits.

Figure 4.

X-ray structures of WDR5 in complex with the C-MYC peptide and fragment hits. (A) C-MYC peptide, PDB: 4Y7R; (B) **F1** (PDB: 6UJJ); (C) **F2** (PDB: 6UHY); (D) **F5** (PDB: 6UJH); (E) **F6** (PDB: 6UHZ); (F) **F7** (PDB: 6UJL). WDR5 is displayed as the surface model, with the WBM site centered.

Figure 5. Merging strategy. (A) Merging the previously reported HTS hit **1** with **F2** results in a new class of compounds. Incorporation of the previously reported best-in-class sulfonyl piece was expected to result in improved compounds. (B) X-ray co-crystal structure of **F2** bound to WDR5 (blue) and overlaid with **1** (yellow). (C) Atoms from **F2** and **1** to be merged are colored in green.

Figure 6.
X-ray co-crystal structure of compound **2i** bound to WDR5. PDB: 6UJL

Figure 7.

(A) X-ray co-crystal structure of **4** (green, PDB: 6UJ4) bound to WDR5. (B) Overlay of compound **4** and **30** (yellow, PDB: 6U5Y). (C) X-ray co-crystal structure of **8** (magenta, PDB: 6UIF) bound to WDR5. (D) X-ray co-crystal structure of **12** (white, PDB: 6UOZ).

Figure 8.

(A) Compound target engagement in cell lysates. Levels of c-MYC proteins co-precipitating with WDR5 were assessed in cell lysates from WDR5-FLAG and c-MYC-HA co-overexpressing HEK293 cells. A fraction of the lysate before addition of compound is shown as a control lane. Immunoprecipitation with α -FLAG was used to isolate WDR5, which is not detectable in the input due to the excess of WDR5 in the immunoprecipitation (IP) fraction. Quantification was performed using ImageJ with the Fiji plugin and normalized to the vehicle control. Data are representative of minimum two independent biological repeats. (B) Compound target engagement in living cells. Transformed HEK293 cells were treated for 24 h with 5 μ M compound and lysates were prepared and analyzed as in (A). A fraction of the input lysate was blotted to monitor MYC levels in treated cells. Data are representative of minimum two independent biological repeats (C) Binding of MYC to target genes. Chromatin Immunoprecipitation (ChIP) in c-MYC-HA overexpressing HEK293 cells treated with 20 μ M compound for 10 h was performed using an α -HA antibody. Percent recovery was monitored by qPCR at genes dependent on WDR5 for MYC recruitment or two genes independent of WDR5 (ZFPM1 and ZNF771). (D) WDR5 binding

to chromatin at MYC target genes. The p values were calculated using a one-tailed student t-test. Data are representative of minimum three independent biological repeats.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Scheme 1.

Synthesis of Compounds **2a-p**. Reagents and conditions: (a) Bromoalkane (any **a, d, f, h-n**), KI, Cs₂CO₃, MeCN, MW, 135 °C, 45 min, 10–100%; (b) HOAc, HNO₃, Ac₂O, 0 °C - r.t., 77%; (c) alkyl amine or aniline (**c, e, or g**), MeOH:H₂O (1:1, v/v), 0 °C - r.t., 12–72%; (d) Acyl chloride (**o or p**), Et₃N, MeCN, 75 °C, 3–19%; (e) ArI (**b**), CuI, *L*-proline, K₂CO₃, DMSO, 85 °C, 19%; (f) 10% Pd/C, EtOH, H₂, 3 M HCl; (g) Pyridine, DCM, 0 °C - r.t., 1–48%.

Scheme 2.

Synthesis of compounds **3a-f**. Reagents and conditions: (a) Bromocyclopentane, KI, Cs₂CO₃, MeCN, MW, 135 °C, 45 min, 75%; (b) Pd/C 10%, EtOH, H₂, 3 M HCl; (c) Pyridine, DCM, 0 °C - r.t., 1–84%; (d) Cyclopent-1-en-ylboronic acid, 2 M Na₂CO₃ (aq), Pd(PPh₃)₄, H₂O, dioxane, 100 °C, 82%; (e) 4 M HCl in dioxane, 50 °C.

Scheme 3.

Synthesis of compounds **4**, **5**, and **6–12**. Reagents and conditions: (a) Bromocyclopentane, KI, Cs₂CO₃, MeCN, MW, 135 °C, 45 min. 24–82%; (b) Pd/C 10%, EtOH, H₂, 3 M HCl; (c) **17**, pyridine, DCM, 0 °C - r.t., 20–48%; (d) Vinyl boronic pinacol ester, Pd(PPh₃)₄, Cs₂CO₃, Dioxane, H₂O, 135 °C, 53%; (e) NaSMe, Pd₂(dba)₃, Xantphos, Et₃N, THF, 76 °C, 29%; (f) Oxone, EtOH:H₂O (1:1 v/v), 90%; (g) 2 M LiOH, THF, 65 °C, 27%; (h) Amine, PyBOP, DIPEA, CH₂Cl₂, 49%; (i) HCl 2 M in Dioxane, 40 °C, 40 min, 25%.

Table 1.

SAR of substituents at *N*-1 of the imidazole ring.

Compound	R	FPA $K_d(\mu\text{M})^*$	Compound	R	FPA $K_d(\mu\text{M})^*$
2a		1.0 $\pm$ 0.3	2i		0.4 $\pm$ 0.1
2b		3.2 $\pm$ 0.5	2j		11 $\pm$ 3
2c		4.0 $\pm$ 0.7	2k		2.1 $\pm$ 0.7
2d		5.2 $\pm$ 0.9	2l		4.5 $\pm$ 0.8

Compound	R	FPA $K_d(\mu\text{M})^*$	Compound	R	FPA $K_d(\mu\text{M})^*$
2e		1.2 ± 0.2	2m		3.4 ± 0.7
2f		5.5 ± 0.7	2n		8 ± 2
2g		4.0 ± 0.6	2o		38 ± 3
2h		0.4 ± 0.1	2p		>40

* Data displayed is the average of at least 3 independent replicates $\pm$ standard deviation.

Table 2.

SAR of heterocycles.

3

Compound	R	FPA K_d (μ M)*
2i		0.4 ± 0.1
3a		6.5 ± 0.8
3b		10 ± 1
3c		2.8 ± 0.4

3

Compound	R	FPA K _d (μM)*
3d		0.5 ± 0.1
3e		0.6 ± 0.1
3f		32 ± 7

* Data displayed is the average of at least 3 independent replicates ± standard deviation.

Table 3.

C-2 substitution.

Compound	R	FPA K_d (μ M)*
4		0.17 $\pm$ 0.04
5		0.22 $\pm$ 0.08
6		0.11 $\pm$ 0.03
7		0.7 $\pm$ 0.2
8		0.17 $\pm$ 0.03

Compound	R	FPA K _d (μM)*
9		5 ± 1
10		1.1 ± 0.1
11		2.3 ± 0.5
12		0.10 ± 0.01

* Data displayed is the average of at least 3 independent replicates ± standard deviation.